<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD with MathML3 v1.1 20151215//EN" "JATS-journalpublishing1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         dtd-version="1.1"
         xml:lang="en"
         article-type="other">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher-id">Zdrav Vestn</journal-id>
         <journal-id journal-id-type="nlm-ta">Zdrav Vestn</journal-id>
         <journal-id journal-id-type="doi">Zdrav Vestn</journal-id>
         <journal-title-group>
            <journal-title>Slovenian Medical Journal</journal-title>
            <trans-title-group xml:lang="sl">
               <trans-title>Zdravniški vestnik</trans-title>
            </trans-title-group>
            <abbrev-journal-title>Zdrav Vestn</abbrev-journal-title>
         </journal-title-group>
         <issn publication-format="ppub" pub-type="ppub">1318-0347</issn>
         <issn publication-format="epub" pub-type="epub">1581-0224</issn>
         <issn-l>0350-0063</issn-l>
         <publisher>
            <publisher-name xml:lang="sl">Slovensko zdravniško društvo</publisher-name>
            <publisher-name xml:lang="en">Slovenian Medical Association</publisher-name>
            <publisher-loc xml:lang="sl">Ljubljana, Slovenia</publisher-loc>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="doi">10.6016/ZdravVestn.2842</article-id>
         <article-id pub-id-type="publisher-id">2842</article-id>
         <article-categories>
            <subj-group subj-group-type="discipline" xml:lang="en">
               <subject>Medicine and health sciences</subject>
               <subj-group>
                  <subject>Oncology</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="en">
               <subject>Review article</subject>
            </subj-group>
            <subj-group subj-group-type="heading" xml:lang="en">
               <subject>Oncology</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title xml:lang="en">Human breast cancer cell lines</article-title>
            <alt-title alt-title-type="running-head" xml:lang="en">Human breast cancer cell lines</alt-title>
         </title-group>
         <contrib-group>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Skok</surname>
                  <given-names>Kristijan</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
               <xref ref-type="corresp" rid="corr"/>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Maver</surname>
                  <given-names>Uroš</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Gradišnik</surname>
                  <given-names>Lidija</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Kavalar</surname>
                  <given-names>Rajko</given-names>
               </name>
               <xref ref-type="aff" rid="aff2">2</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Sobočan</surname>
                  <given-names>Monika</given-names>
               </name>
               <xref ref-type="aff" rid="aff3">3</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Takač</surname>
                  <given-names>Iztok</given-names>
               </name>
               <xref ref-type="aff" rid="aff3">3</xref>
            </contrib>
         </contrib-group>
         <aff id="aff1" xml:lang="en">
            <label>1</label>
            <institution>Institute of biomedical sciences, Faculty of medicine, University of Maribor, Maribor, Slovenia</institution>
         </aff>
         <aff id="aff2" xml:lang="en">
            <label>2</label>
            <institution>Department of Patology, University Medical Centre Maribor, Maribor, Slovenia</institution>
         </aff>
         <aff id="aff3" xml:lang="en">
            <label>3</label>
            <institution>Division of Gyneacology and Perinatology, University Medical Centre Maribor, Maribor, Slovenia</institution>
         </aff>
         <author-notes>
            <fn fn-type="conflict" xml:lang="en">
               <p>The authors have declared that no competing interests exist.</p>
            </fn>
            <fn fn-type="conflict" xml:lang="sl">
               <p>Avtorji so izjavili, da ne obstajajo nobeni konkurenčni interesi.</p>
            </fn>
            <corresp id="corr">Kristijan Skok, e-mail: <email xlink:type="simple"/>
            </corresp>
         </author-notes>
         <pub-date pub-type="ppub">
            <month>10</month>
            <year>2019</year>
         </pub-date>
         <pub-date pub-type="epub">
            <month>10</month>
            <year>2019</year>
         </pub-date>
         <volume>88</volume>
         <issue>9–10</issue>
         <fpage>427</fpage>
         <lpage>43</lpage>
         <history>
            <date date-type="received">
               <day>10</day>
               <month>5</month>
               <year>2018</year>
            </date>
            <date date-type="accepted">
               <day>7</day>
               <month>1</month>
               <year>2019</year>
            </date>
         </history>
         <permissions>
            <copyright-statement xml:lang="en">Copyright © 2019, Slovenian Medical Association (SZD)</copyright-statement>
            <copyright-statement xml:lang="sl">© 2019, Slovensko zdravniško društvo (SZD)</copyright-statement>
            <copyright-year>2019</copyright-year>
            <copyright-holder xml:lang="en">Slovenian Medical Association (SZD)</copyright-holder>
            <copyright-holder xml:lang="sl">Slovensko zdravniško društvo (SZD)</copyright-holder>
            <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                     xlink:type="simple"
                     xml:lang="en">
               <license-p>This is an open access article distributed under the terms of the
          <ext-link ext-link-type="uri"
                            xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                            xlink:type="simple">Creative Commons Attribution-NonCommercial
            License</ext-link>, which permits unrestricted use, distribution, and
          reproduction in any medium, provided the original author and source are
          credited and only for non-commercial purposes. </license-p>
            </license>
            <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                     xlink:type="simple"
                     xml:lang="sl">
               <license-p>To je članek z odprtim dostopom, ki ga lahko uporabite pod pogoji iz
          <ext-link ext-link-type="uri"
                            xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                            xlink:type="simple">Creative Commons Priznanje avtorstva-Nekomercialno
            licence</ext-link>. ki dovoljuje distribucijo, predelavo ali
          prilagoditev, ter gradijo na njem, v nekomercialne namene, z navedbo avtorja
          in izvirnega dela.</license-p>
            </license>
         </permissions>
         <abstract xml:lang="en">
            <title>Abstract</title>
            <p>Breast cancer is the second most common cancer worldwide and ranked first in incidence in women living either in developed or developing countries. It is ranked as the fifth common cause of cancer death. Annually, there are 1310 new cases of breast cancer in Slovenia. There are many types of breast cancer that we can differentiate based on their histopathology and molecular i.e. intrinsic properties. Breast cancer cell lines play a significant role in breast cancer research and analysis of different subtypes. The first breast cancer cell line was established in 1958 and named BT-20 (1958, Lasfargues in Ozzello). In recent years the number of cell lines has drastically increased. Commonly used breast cancer cell lines are MCF7, T47D and MDAMB231. The MCF7 and T47D cell lines are luminal A type (ER+/PR+/HER2-), whereas MDAMB231 is triple negative (ER-/PR-/HER2-). There are many inconsistencies in nomenclature and culturing of cell lines. Also, questionable is the consistency and repeatability of research in different laboratories or conditions, where cell lines could develop different traits (e.g. dedifferentiation, change of phenotype, mutations). There are examples of different categorisation into unique subtypes of the same cell lines in literature, based on different molecular and morphological descriptions. Therefore, the authors believe that there is a need for a literature review of the currently available information. The authors focused on breast cancer cell lines, their nomenclature, differentiation, culturing and usefulness.</p>
         </abstract>
         <kwd-group xml:lang="en">
            <kwd>breast cancer cell lines</kwd>
            <kwd>breast cancer</kwd>
            <kwd>triple negative breast cancer</kwd>
            <kwd>in vitro cell lines</kwd>
            <kwd>cell culture</kwd>
         </kwd-group>
      </article-meta>
   </front>
   <body>
      <sec id="s1" sec-type="Introduction">
         <label>1</label>
         <title>Introduction</title>
         <p>Breast cancer (BC) is the second most common cancer in the world and by far the most common in women, both in the developed world (incidence of 794,000 per year) and in developing countries, where its incidence is slightly higher (883,000 per year). Globally, BC ranks fifth in cancer mortality (522,000 deaths) (<xref ref-type="bibr" rid="b1">1</xref>). There are approximately 1,310 new cases of BC and 380 deaths annually in Slovenia (<xref ref-type="bibr" rid="b2">2</xref>). Since 1968, it has been the most cancer location in women (20–25 % of all cancer cases) (<xref ref-type="bibr" rid="b2">2</xref>).</p>
         <p>There are many subtypes of BC that we can differentiate based on their histopathology and molecular i.e. intrinsic properties. One of these subtypes is the triple-negative BC (TNBC) of which the absence of hormone receptors for oestrogen (ER) and progesterone (PR) and the lack of of human epidermal growth factor receptor 2 (HER2) are characteristic. The prognosis and survival rate in the Western world are relatively good, but the outcome prediction of the TNBC subtype is the poorest as it progresses rapidly, spreads and is more aggressive (<xref ref-type="bibr" rid="b3">3</xref>,<xref ref-type="bibr" rid="b4">4</xref>). It is for this reason that research trying to specify this type of cancer is of great importance. As part of this research, there are more and more new methods using molecular and other interdisciplinary approaches. One of the prospective approaches to BC research are <italic>in vitro</italic> and <italic>in vivo</italic> models (<xref ref-type="bibr" rid="b5">5</xref>-<xref ref-type="bibr" rid="b7">7</xref>). This article focuses on the overview of BC and <italic>in vitro</italic> methods of BC cell line (CL) cultivation in order to understand the development of BC CL to improve the knowledge and then the treatment of BC.</p>
      </sec>
      <sec id="s2"
           sec-type="Classification of Malignant Transformation of Breast Cancer">
         <label>2</label>
         <title>Classification of Malignant Transformation of Breast Cancer</title>
         <p>BC can be classified in different ways. In standard treatment of patients with BC, in addition to histological tumour type, tumour size, maturity (Gradus: Elston and Ellis), presence or absence of lympho-vascular infiltration, presence of intraepithelial component, microscopic margin status, immunohistochemical expression of hormone receptors (ER, PR), HER2 receptor expression, and HER2 gene amplification. As a predictive factor Ki67 proliferation index is determined as well. Proteases and gene signatures may also be identified, which may also help in deciding on additional, i.e. complementary treatment. These are also important in considering the cultivation of CL, for a successful cultivation of a particular CL requires detailed information about of the type of tissue of origin and its characteristics (cultivation, use of appropriate medium, characterization) (<xref ref-type="bibr" rid="b8">8</xref>,<xref ref-type="bibr" rid="b9">9</xref>).</p>
         <sec id="s2.1" sec-type="Histopathological classification">
            <label>2.1</label>
            <title>Histopathological classification</title>
            <p>Primary BC is divided into non-invasive and invasive types. Non-invasive include ductal intraepithelial carcinoma (DCIS) and lobular intraepithelial carcinoma (LCIS). The characteristic of these types of cancer is that they do not penetrate the basement membrane and do not spread to distant organs (<xref ref-type="bibr" rid="b8">8</xref>).</p>
            <p>Invasive cancer types are more common. The most common no special type (NST) of invasive cancer, accounting for 40–75 % of all invasive BC, is often associated with DCIS. The NST group also includes mixed-type carcinomas and rare cancers such as pleomorphic sarcoma, carcinoma with osteoclast-like giant cells, cancer with choriocarcinoma properties, and cancer with melanotic properties.</p>
            <p>The second most common BC is the invasive lobular carcinoma (ILC), which occurs in a slightly older population of women (aged 57–65) and accounts for 5–15 % of all invasive types of BC. ILC is not a homogeneous form of BC, as it is formed by the classic, solid and pleomorphic types, the tubulolobular variant and a mixed form of the above types.</p>
            <p>Tubular carcinoma and cribriform carcinoma are two types of BC, which are rare types of BC (2 % and 0.3–4 %) and have very good prognosis.</p>
            <p>The group of carcinomas with medullary features include classic medullary carcinoma, atypical medullary carcinoma and invasive carcinoma of NST with medullary features. The characteristic of classic medullary carcinoma, which is a rare type of cancer (less than 1 % of all BCs), has a relatively good outlook, which is thought to depend on the density of the lymphoplasmocytic infiltrate, which is one of the diagnostic criteria of the tumour.</p>
            <p>Pure types of mucinous carcinoma account for 2 % of all BCs and usually develops in women over 55. It has a good 5-year survival rate and a very low rate of local recurrences.</p>
            <p>The group of metaplastic breast carcinomas includes squamous cell carcinoma, spindle cell carcinoma, carcinoma with mesenchymal differentiation, fibromatosis-like metaplastic carcinoma and low-grade adenosquamous carcinoma, and it accounts for 0.2–5 % of all BCs. They spread less frequently to the axillary lymph nodes nodes than the invasive NST carcinoma.</p>
            <p>Other, even rarer types of invasive BCs are: micropapillary carcinoma, salivary gland type tumors, adenoid cystic carcinoma, carcinoma with apocrine differentiation, carcinomas with neuroendocrine differentiation, papillary carcinoma and inflammatory carcinoma (<xref ref-type="bibr" rid="b8">8</xref>,<xref ref-type="bibr" rid="b9">9</xref>).</p>
         </sec>
         <sec id="s2.2" sec-type="Intrinsic and molecular classification">
            <label>2.2</label>
            <title>Intrinsic and molecular classification</title>
            <p>We distinguish several BC subtypes based on the gene expression profile. Based on the immunohistochemical profile we divide BC according to the presence/absence of ER and PR. Immunohistochemistry and <italic>in situ</italic> hybridization determine the overexpression of the HER2 oncoprotein and/or the multiplication of the HER2 gene (<xref ref-type="bibr" rid="b9">9</xref>). Negative receptor and HER2 status are characteristic of TNBC (<xref ref-type="bibr" rid="b4">4</xref>).</p>
            <p>With the development of DNA microarrays, gene expression profiling (GEP) has become widely used to predict the outcome of BC. One of the key purposes is to identify patients with quite a good enough prognosis of outcome that would allow chemotherapy to be discontinued. A pioneering study in this area was done by Sørlie et al., who identified in their study a characteristic molecular profile of BC with 456cDNA fragments (<xref ref-type="bibr" rid="b10">10</xref>).</p>
            <p>On this basis, BC was classified into 5 different intrinsic subtypes with a characteristic clinical course and outcome (luminal A, luminal B, tumours with HER2 gene amplification, i.e. with a positive HER2 status, basal and normal epithelial-like tumours) (<xref ref-type="bibr" rid="b11">11</xref>,<xref ref-type="bibr" rid="b12">12</xref>). Each subtype has its own prognosis and response to treatment. The luminal A subtype (BC, in which the Ki67 immunoreactivity index is less than 15 %) and B subtype (BC, in which the proliferation index, reflecting the Ki67 immunoreactivity, is greater than 15 %) are subtypes that respond to hormone therapy.</p>
            <p>The HER2-positive BC is suitable for treatment with trastuzumab. The basal phenotype is described as TNBC because it is characterised by negative hormonal (ER and PR) and negative HER2 status. Although there are similarities between the basal type of BC and TNBC, the two BC categories are not to be considered equal, since the TNBC includes also other subtypes (<xref ref-type="bibr" rid="b5">5</xref>).</p>
            <p>Despite the many names and a different number of categories, BC generally falls into one of 3 major intrinsic types (i.e., luminal, HER2-positive and TNBC phenotype, which are the most heterogeneous and mostly of the basal subtypes). An overview of the division of tumours is given in <xref ref-type="table" rid="table1">Table 1</xref> (<xref ref-type="bibr" rid="b13">13</xref>-<xref ref-type="bibr" rid="b15">15</xref>).</p>
            <table-wrap position="anchor" id="table1">
               <label>Table 1:</label>
               <caption>
                  <p> Overview of BC subtype classification</p>
               </caption>
               <table>
                  <colgroup>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th>Intrinsic Subtype</th>
                        <th>IHC status</th>
                        <th>Grade</th>
                        <th>Prevalence</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td>Luminal A</td>
                        <td>(ER+, PR+), HER2-, KI67- (&lt; 15 %)</td>
                        <td align="right">1/2</td>
                        <td align="right">23,7 %</td>
                     </tr>
                     <tr>
                        <td>Luminal B</td>
                        <td>
                           <p>(ER+,PR+), HER2-, KI67+(&gt; 15 %)</p>
                           <p>(ER+, PR-), HER2-, KI67+(&gt; 15 %)</p>
                        </td>
                        <td align="right">2/3</td>
                        <td>
                           <p>38,8 %</p>
                           <p>14 %</p>
                        </td>
                     </tr>
                     <tr>
                        <td>HER2</td>
                        <td>(ER-, PR-), HER2+</td>
                        <td align="right">2/3</td>
                        <td align="right">11,2 %</td>
                     </tr>
                     <tr>
                        <td>Basal</td>
                        <td>(ER-,PR-), HER2-, basal markers+</td>
                        <td align="right">3</td>
                        <td align="right">12,3 %</td>
                     </tr>
                     <tr>
                        <td>Normal-like</td>
                        <td>(ER+,PR+), HER2-, KI67- (&lt; 15 %)</td>
                        <td align="right">1/2/3</td>
                        <td align="right">7,8 %</td>
                     </tr>
                  </tbody>
               </table>
               <table-wrap-foot>
                  <p>Legend: IHC - immunohistochemical status, ER – oestrogen receptor, PR – progesterone receptor. The limit value of Ki67 is 15 %. Table 1 is a summary of Dai et al. (<xref ref-type="bibr" rid="b15">15</xref>), using the CCBY-NC 4.0 licence.</p>
               </table-wrap-foot>
            </table-wrap>
         </sec>
      </sec>
      <sec id="s3" sec-type="Cell lines">
         <label>3</label>
         <title>Cell lines</title>
         <p>A significant proportion of new findings on BC is the result of <italic>in vitro</italic> and <italic>in vivo</italic> studies on CLs (<xref ref-type="bibr" rid="b6">6</xref>,<xref ref-type="bibr" rid="b7">7</xref>,<xref ref-type="bibr" rid="b16">16</xref>,<xref ref-type="bibr" rid="b17">17</xref>). Commonly used CLs are MCF7, T47D, and MDAMB231 (<xref ref-type="bibr" rid="b5">5</xref>,<xref ref-type="bibr" rid="b6">6</xref>,<xref ref-type="bibr" rid="b18">18</xref>). Their characteristics are: MCF-7 – BC CL of LA type was isolated from a 69-year-old Caucasian woman in 1970; LA-type T47D CL was isolated from a pleural effusion of a 54-year-old woman with ductal breast carcinoma; MDAMB231 BC CL of TNBC type basal subtype B (TNBC-B) was isolated from an adenocarcinoma of a 51-year-old woman; the BT-20 BC CL of TNBC type basal subtype A (TNBC-A), however, was isolated from an BC of a 74-year-old female in 1958.</p>
         <sec id="s3.1" sec-type="Nomenclature of cell lines and their description">
            <label>3.1</label>
            <title>Nomenclature of cell lines and their description</title>
            <p>The first human CL was established in a Baltimore over sixty years ago (1951) by George Gey. It was named after the patient whose cervical cancer tissue was used. The patient’s name was Henrietta Lacks and the CL was named HeLa (<xref ref-type="bibr" rid="b19">19</xref>).</p>
            <p>The first BC CL was established in 1958 and named BT-20 (<xref ref-type="bibr" rid="b20">20</xref>). Twenty years later there was another breakthrough and CLs became more accessible (<xref ref-type="bibr" rid="b21">21</xref>,<xref ref-type="bibr" rid="b22">22</xref>). A series of MDA CL (M. D. Anderson Hospital and Tumor Institute) came out. In 1973, the Michigan Cancer Foundation established the MCF-7, still one of the most widely used in the world today. It is characterised by a high ER sensitivity, allowing research and modeling to investigate hormone responsiveness (<xref ref-type="bibr" rid="b23">23</xref>). In most cases the naming of CL is not related to phenotypic characteristics but to how and where they were established (laboratory, patient, subculture isolates, etc.). Some examples of such naming are: the HCC Series, which was established at the Hamon Cancer Center; MDA Series, named after M. D. Anderson Hospital and Tumor Institute; the MHT Series is known for its many subcultivations under various conditions (e.g., P53 mutations, MYC amplification, EGF independence, etc.) (<xref ref-type="bibr" rid="b5">5</xref>). Until recently, there were no specific recommendations for naming CL and they could also be named after the scientist who created them. The new recommendations will make it possible to avoid this, make it easier to understand and do research in this field (<xref ref-type="bibr" rid="b24">24</xref>).</p>
            <p>Below, we summarize and list some of the more important points and guidelines for naming CL from the the current recommendations (<xref ref-type="bibr" rid="b24">24</xref>). Using a short name or just one letter is inappropriate and makes it impossible to search and identify them online.</p>
            <p>The main recommendations are as follows:</p>
            <list>
               <list-item>
                  <label>1.</label>
                  <p>The name of the donor or other personal data (e.g. the year of birth) should not be used, since it could compromise the patient’s anonymity;</p>
               </list-item>
               <list-item>
                  <label>2.</label>
                  <p>The CL name must contain at least 6 characters but not a commonly used term (e.g. glioma);</p>
               </list-item>
               <list-item>
                  <label>3.</label>
                  <p>The characters of the name must be such that they do not cause difficulty in indexing or computer search (e.g. special characters, letters, etc.), the characters may be written in upper case or lower case, and Arabic numerals, dashes and underscores are appropriate;</p>
               </list-item>
               <list-item>
                  <label>4.</label>
                  <p>Spaces, asterisks, superscripts or subscripts, slashes, question marks, exclamation marks, spaces, commas, semicolons, Greek letters or other symbols must not be used;</p>
               </list-item>
               <list-item>
                  <label>5.</label>
                  <p>The given name must be unique.</p>
               </list-item>
            </list>
            <p>Verification is done by searching the web (Google, PubMed, etc.) and the Cellosaurus website (web.expasy.org/cellosaurus). During the search variations of the name must also be checked (e.g. T406, T 406, T-406) and potentially abbreviated forms (e.g. NCI-H420 or H420) (<xref ref-type="bibr" rid="b24">24</xref>).</p>
            <p>For the embryonic stem cells and induced pluripotent stem cells a standardized nomenclature has already been established. The recommended naming style for other lines is as follows:</p>
            <p>1.The use of an Origin identifier is recommended, that refers to the institute or laboratory where the CL was grown (e.g. SK-Sloan Kettering, WI for Wistar Institute, MFUM - Medical Faculty, University of Maribor);</p>
            <list>
               <list-item>
                  <label>2.</label>
                  <p>The use of a batch or tissue identificator (e.g., GI-glioma, Lu-lung, Br-breast);</p>
               </list-item>
               <list-item>
                  <label>3.</label>
                  <p>The use of a number to identify a specific CL (e.g., a number read from a container in which the tissue was located);</p>
               </list-item>
               <list-item>
                  <label>4.</label>
                  <p>An additional number, mostly an alphanumeric combination of two characters, would identify the subtype, clone or transformed cultures (<xref ref-type="bibr" rid="b24">24</xref>).</p>
               </list-item>
            </list>
         </sec>
         <sec id="s3.2"
              sec-type="Molecular classification of breast cancer cell lines">
            <label>3.2</label>
            <title>Molecular classification of breast cancer cell lines</title>
            <p>Gene expression profiling has in recent times been widely applied to catalogue BC CLs. Dai et al. have analysed in their article 84 CLs based on the status of ER, PR, and HER2 statuses and classified them using the classification LA, LB, HER2+ and TNBC (A and B subtypes) (<xref ref-type="bibr" rid="b5">5</xref>).</p>
            <p>TNBC CLs are referred to in the literature as basal A or basal B. TNBC-A is more similar to the luminal-like subtype and the TNRD-B is more basal-like. The similarity between the types also causes confusion in the classification itself. An example of this is the MDAMB468 CL, which is sometimes classified as basal A and in other articles as weakly luminal. Hs578T and MDAMB231 CLs are sometimes described as basal B and in other articles as claudin-low or even mesenchymal-like. The intrinsic subtypes of cancer and CLs are shown in <xref ref-type="fig" rid="fig1">Figure 1</xref> and <xref ref-type="table" rid="table2">Table 2</xref>. <xref ref-type="table" rid="table3">Table 3</xref> lists the more well-known CLs.</p>
            <fig position="anchor" id="fig1">
               <label>Figure 1:</label>
               <caption>
                  <p> Comparison between current methods of categorizing BC and its CLs.</p>
               </caption>
               <p>
                  <graphic xlink:href="2842-en-web-resources/image/zdravvestn-2842-en-01.png"/>
               </p>
               <p>Glede na status hormonskih receptorjev in HER2 se RD deli na luminalni tip A in B, HER2+ ter TNRD, ki ga lahko delimo na bazalni, nizko klavdinski, metaplastični in z interferonom bogat RD. Slika 1 je povzeta po Dai in sod. (<xref ref-type="bibr" rid="b5">5</xref>), uporabljeno z licenco CC BY-NC 4.0.</p>
            </fig>
            <table-wrap position="anchor" id="table2">
               <label>Table 2:</label>
               <caption>
                  <p> 	Molecular and morphological characteristics of BC CLs.</p>
               </caption>
               <table>
                  <colgroup>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th>CL SUBTYPE</th>
                        <th/>
                        <th colspan="2">mRNA</th>
                        <th>miRNA</th>
                        <th>PROTEIN</th>
                        <th>MORPHOLOGY</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td>Luminal</td>
                        <td/>
                        <td colspan="2">ER, GATA3, KRT19/KRT8/KRT18, XBP1, PBX1, ZNF278, SPDEF, CRABP2, MUC1, FOXA1, MYB, RET, EGR3, TFF1, HER3, TOB1, TFF3</td>
                        <td>
                           <p>hsa-miR-501–5p,</p>
                           <p>hsa-miR-202</p>
                           <p>hsa-miR-760</p>
                           <p>hsa-miR-626</p>
                        </td>
                        <td>ER, GATA3, KRT19</td>
                        <td>More differentiated; tight cell-cell junctions</td>
                     </tr>
                     <tr>
                        <td>HER2+</td>
                        <td/>
                        <td colspan="2">HER2, GRB7, PERLD1, STARD3, C17ORF37 hsa-let-7b</td>
                        <td>
                           <p>hsa-miR-640</p>
                           <p>hsa-miR-200c</p>
                           <p>hsa-miR-378</p>
                           <p>hsa-miR-141</p>
                           <p>hsa-miR-196a</p>
                           <p>hsa-miR-29c</p>
                           <p>hsa-miR-18a*</p>
                        </td>
                        <td>HER2</td>
                        <td>Breakdown of cell-cell junctions</td>
                     </tr>
                     <tr>
                        <td>TNRD</td>
                        <td>Triple negative A (basal A)</td>
                        <td rowspan="2">
                           <p>EGFR</p>
                           <p>CAV1/2</p>
                           <p>MSN</p>
                           <p>ETS1</p>
                        </td>
                        <td>KRT4/5/6A/6B/13/14/15/16/17, ITGA6, ITGB4/6, LAMB3, LAMC2, TRIM29, S100A2, SLPI, LYN, ANXA8, COL17A1, BNC1, MET, CD133, GABRK, VTCN1, BST2, FABP7, CD10/14/58/59.</td>
                        <td>
                           <p>hsa-miR-492</p>
                           <p>hsa-miR-26b</p>
                           <p>hsa-miR-617</p>
                           <p>hsa-miR-155</p>
                        </td>
                        <td>
                           <p>EGFR</p>
                           <p>CAV1/2</p>
                           <p>MSN</p>
                           <p>ETS1</p>
                           <p>KRT5/6</p>
                           <p>CD10</p>
                           <p>MET</p>
                        </td>
                        <td>Core basal-like</td>
                     </tr>
                     <tr>
                        <td/>
                        <td>
                           <p>Triple negative B</p>
                           <p>(basal B)</p>
                        </td>
                        <td>
                           <p>VIM, SPARC, FN1, FBN1, HSA2, PRG1,</p>
                           <p>COL3A1, COL6A1/2/3, COL8A1, MMP2/14,</p>
                           <p>TIMP1, CTSC, PLAU, PLAUR, AXL, PLAT,</p>
                           <p>CD24(-), CD44, TGFBR2, SERPINE1/2, TGFB1</p>
                        </td>
                        <td>
                           <p>hsa-miR-22</p>
                           <p>hsa-miR-532–3p</p>
                           <p>hsa-miR-125b</p>
                           <p>hsa-miR-501–5p</p>
                           <p>hsa-miR-155*</p>
                        </td>
                        <td>CD44</td>
                        <td>Least differentiated and most similar to stem cells; more mesenchymal-like appearance and highly invasive</td>
                     </tr>
                  </tbody>
               </table>
               <table-wrap-foot>
                  <p>Legend: CL – cell lines, TNBC – triple negative breast cancer. Table 2 is a summary of Dai et al. (<xref ref-type="bibr" rid="b5">5</xref>), using the CCBY-NC 4.0 licence.</p>
               </table-wrap-foot>
            </table-wrap>
            <table-wrap position="anchor" id="table3">
               <label>Table 3:</label>
               <caption>
                  <p> List of Breast Cancer Cell Lines.</p>
               </caption>
               <table>
                  <colgroup>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th>CELL LINES</th>
                        <th>ER</th>
                        <th>PR</th>
                        <th>HER2</th>
                        <th>BRCA1</th>
                        <th>SUBT</th>
                        <th>SER</th>
                        <th>MEDIUM</th>
                        <th>TUM</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td>BT483</td>
                        <td>+</td>
                        <td>+/-</td>
                        <td>-</td>
                        <td>WT</td>
                        <td>LA</td>
                        <td>BT</td>
                        <td>RPMI</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>CAMA1</td>
                        <td>+</td>
                        <td>+/-</td>
                        <td>-</td>
                        <td>WT</td>
                        <td>LA</td>
                        <td>NA</td>
                        <td>DMEM</td>
                        <td>AC</td>
                     </tr>
                     <tr>
                        <td>EFM19</td>
                        <td>+</td>
                        <td>+</td>
                        <td>-</td>
                        <td>ND</td>
                        <td>LA</td>
                        <td>EFM</td>
                        <td>RPMI</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>HCC1428</td>
                        <td>+</td>
                        <td>+</td>
                        <td>-</td>
                        <td>ND</td>
                        <td>LA</td>
                        <td>HCC</td>
                        <td>RPMI</td>
                        <td>AC</td>
                     </tr>
                     <tr>
                        <td>HCC712</td>
                        <td>+</td>
                        <td>+/-</td>
                        <td>-</td>
                        <td>ND</td>
                        <td>LA</td>
                        <td>HCC</td>
                        <td>RPMI</td>
                        <td>DC</td>
                     </tr>
                     <tr>
                        <td>IBEP2</td>
                        <td>+</td>
                        <td>-</td>
                        <td>-</td>
                        <td>ND</td>
                        <td>LA</td>
                        <td>NA</td>
                        <td>DMEM</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>KPL1</td>
                        <td>+</td>
                        <td>-</td>
                        <td>-</td>
                        <td>ND</td>
                        <td>LA</td>
                        <td>NA</td>
                        <td>RPMI</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>LY2</td>
                        <td>+</td>
                        <td>-</td>
                        <td>-</td>
                        <td>ND</td>
                        <td>LA</td>
                        <td>NA</td>
                        <td>DMEM</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>MCF7</td>
                        <td>+</td>
                        <td>+</td>
                        <td>-</td>
                        <td>WT</td>
                        <td>LA</td>
                        <td>MCF</td>
                        <td>RPMI, DMEM</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>MDAMB134</td>
                        <td>+</td>
                        <td>-</td>
                        <td>-</td>
                        <td>ND</td>
                        <td>LA</td>
                        <td>MDA</td>
                        <td>RPMI</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>MDAMB134VI</td>
                        <td>+</td>
                        <td>-</td>
                        <td>-</td>
                        <td>WT</td>
                        <td>LA</td>
                        <td>MDA</td>
                        <td>DMEM</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>MDAMB175</td>
                        <td>+</td>
                        <td>-</td>
                        <td>-</td>
                        <td>ND</td>
                        <td>LA</td>
                        <td>MDA</td>
                        <td>RPMI</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>MDAMB175VII</td>
                        <td>+</td>
                        <td>-</td>
                        <td>-</td>
                        <td>WT</td>
                        <td>LA</td>
                        <td>MDA</td>
                        <td>DMEM</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>MDAMB415</td>
                        <td>+</td>
                        <td>+/-</td>
                        <td>-</td>
                        <td>WT</td>
                        <td>LA</td>
                        <td>MDA</td>
                        <td>DMEM</td>
                        <td>AC</td>
                     </tr>
                     <tr>
                        <td>T47D</td>
                        <td>+</td>
                        <td>+</td>
                        <td>-</td>
                        <td>WT</td>
                        <td>LA</td>
                        <td>NA</td>
                        <td>RPMI</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>ZR751</td>
                        <td>+</td>
                        <td>+/-</td>
                        <td>-</td>
                        <td>WT</td>
                        <td>LA</td>
                        <td>ZR75</td>
                        <td>RPMI</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>ZR75B</td>
                        <td>+</td>
                        <td>-</td>
                        <td>-</td>
                        <td>ND</td>
                        <td>LA</td>
                        <td>ZR75</td>
                        <td>RPMI</td>
                        <td>NA</td>
                     </tr>
                     <tr>
                        <td>BSMZ</td>
                        <td>+</td>
                        <td>+</td>
                        <td>+</td>
                        <td>ND</td>
                        <td>LB</td>
                        <td>NA</td>
                        <td>RPMI</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>BT474</td>
                        <td>+</td>
                        <td>+</td>
                        <td>+</td>
                        <td>WT</td>
                        <td>LB</td>
                        <td>BT</td>
                        <td>RPMI</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>EFM192A</td>
                        <td>+</td>
                        <td>+</td>
                        <td>+</td>
                        <td>ND</td>
                        <td>LB</td>
                        <td>EFM</td>
                        <td>RPMI</td>
                        <td>AC</td>
                     </tr>
                     <tr>
                        <td>BEP1</td>
                        <td>-</td>
                        <td>+</td>
                        <td>+</td>
                        <td>ND</td>
                        <td>LB</td>
                        <td>IBEP</td>
                        <td>DMEM</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>IBEP3</td>
                        <td>-</td>
                        <td>+</td>
                        <td>+</td>
                        <td>ND</td>
                        <td>LB</td>
                        <td>IBEP</td>
                        <td>DMEM</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>MDAMB330</td>
                        <td>+</td>
                        <td>-</td>
                        <td>+</td>
                        <td>WT</td>
                        <td>LB</td>
                        <td>MDA</td>
                        <td>RPMI</td>
                        <td>ILC</td>
                     </tr>
                     <tr>
                        <td>MDAMB361</td>
                        <td>+</td>
                        <td>+/-</td>
                        <td>+</td>
                        <td>WT</td>
                        <td>LB</td>
                        <td>MDA</td>
                        <td>RPMI, DMEM</td>
                        <td>AC</td>
                     </tr>
                     <tr>
                        <td>UACC812</td>
                        <td>+</td>
                        <td>+/-</td>
                        <td>+</td>
                        <td>WT</td>
                        <td>LB</td>
                        <td>UACC</td>
                        <td>RPMI, DMEM</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>ZR7527</td>
                        <td>+</td>
                        <td>-</td>
                        <td>+</td>
                        <td>WT</td>
                        <td>LB</td>
                        <td>ZR75</td>
                        <td>RPMI</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>ZR7530</td>
                        <td>+</td>
                        <td>-</td>
                        <td>+</td>
                        <td>WT</td>
                        <td>LB</td>
                        <td>ZR75</td>
                        <td>RPMI</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>21MT1</td>
                        <td>-</td>
                        <td>+/-</td>
                        <td>+</td>
                        <td>ND</td>
                        <td>H</td>
                        <td>21</td>
                        <td>α-MEM/DFC1</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>21MT2</td>
                        <td>-</td>
                        <td>+/-</td>
                        <td>+</td>
                        <td>ND</td>
                        <td>H</td>
                        <td>21</td>
                        <td>α-MEM/DFC1</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>21NT</td>
                        <td>-</td>
                        <td>+/-</td>
                        <td>+</td>
                        <td>ND</td>
                        <td>H</td>
                        <td>21</td>
                        <td>α-MEM/DFC1</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>21PT</td>
                        <td>-</td>
                        <td>+/-</td>
                        <td>+</td>
                        <td>ND</td>
                        <td>H</td>
                        <td>21</td>
                        <td>α-MEM/DFC1</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>AU565</td>
                        <td>-</td>
                        <td>-</td>
                        <td>+</td>
                        <td>WT</td>
                        <td>H</td>
                        <td>NA</td>
                        <td>RPMI</td>
                        <td>AC</td>
                     </tr>
                     <tr>
                        <td>HCC1008</td>
                        <td>-</td>
                        <td>-</td>
                        <td>+</td>
                        <td>ND</td>
                        <td>H</td>
                        <td>HCC</td>
                        <td>RPMI</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>HCC1569</td>
                        <td>-</td>
                        <td>-</td>
                        <td>+</td>
                        <td>WT</td>
                        <td>H</td>
                        <td>HCC</td>
                        <td>RPMI</td>
                        <td>MC</td>
                     </tr>
                     <tr>
                        <td>HCC1954</td>
                        <td>-</td>
                        <td>-</td>
                        <td>+</td>
                        <td>WT</td>
                        <td>H</td>
                        <td>HCC</td>
                        <td>RPMI</td>
                        <td>DC</td>
                     </tr>
                     <tr>
                        <td>HCC202</td>
                        <td>-</td>
                        <td>-</td>
                        <td>+</td>
                        <td>WT</td>
                        <td>H</td>
                        <td>HCC</td>
                        <td>RPMI</td>
                        <td>DC</td>
                     </tr>
                     <tr>
                        <td>HCC2218</td>
                        <td>-</td>
                        <td>-</td>
                        <td>+</td>
                        <td>ND</td>
                        <td>H</td>
                        <td>HCC</td>
                        <td>RPMI</td>
                        <td>DC</td>
                     </tr>
                     <tr>
                        <td>HH315</td>
                        <td>-</td>
                        <td>-</td>
                        <td>+</td>
                        <td>ND</td>
                        <td>H</td>
                        <td>HH</td>
                        <td>RPMI</td>
                        <td>C</td>
                     </tr>
                     <tr>
                        <td>HH375</td>
                        <td>-</td>
                        <td>-</td>
                        <td>+</td>
                        <td>ND</td>
                        <td>H</td>
                        <td>HH</td>
                        <td>RPMI</td>
                        <td>C</td>
                     </tr>
                     <tr>
                        <td>KPL-4</td>
                        <td>-</td>
                        <td>-</td>
                        <td>+</td>
                        <td>WT</td>
                        <td>H</td>
                        <td>KPL</td>
                        <td>DMEM</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>MDAMB453</td>
                        <td>-</td>
                        <td>-</td>
                        <td>+</td>
                        <td>WT</td>
                        <td>H</td>
                        <td>MDA</td>
                        <td>RPMI, DMEM</td>
                        <td>AC</td>
                     </tr>
                     <tr>
                        <td>OCUB-F</td>
                        <td>-</td>
                        <td>-</td>
                        <td>+</td>
                        <td>WT</td>
                        <td>H</td>
                        <td>NA</td>
                        <td>RPMI</td>
                        <td>NA</td>
                     </tr>
                     <tr>
                        <td>SKBR3</td>
                        <td>-</td>
                        <td>-</td>
                        <td>+</td>
                        <td>WT</td>
                        <td>H</td>
                        <td>SKBR</td>
                        <td>RPMI, McCoys</td>
                        <td>AC</td>
                     </tr>
                     <tr>
                        <td>SKBR5</td>
                        <td>-</td>
                        <td>-</td>
                        <td>+</td>
                        <td>WT</td>
                        <td>H</td>
                        <td>SKBR</td>
                        <td>RPMI</td>
                        <td>AC</td>
                     </tr>
                     <tr>
                        <td>SUM190PT</td>
                        <td>-</td>
                        <td>-</td>
                        <td>+</td>
                        <td>WT</td>
                        <td>H</td>
                        <td>SUM</td>
                        <td>Ham's F12</td>
                        <td>Inf</td>
                     </tr>
                     <tr>
                        <td>SUM225CWN</td>
                        <td>-</td>
                        <td>-</td>
                        <td>+</td>
                        <td>WT</td>
                        <td>H</td>
                        <td>SUM</td>
                        <td>Ham's F12</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>UACC893</td>
                        <td>-</td>
                        <td>-</td>
                        <td>+</td>
                        <td>WT</td>
                        <td>H</td>
                        <td>UACC</td>
                        <td>RPMI</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>BT20</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>WT</td>
                        <td>TNRD-A</td>
                        <td>BT</td>
                        <td>RPMI, DMEM</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>CAL148</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>WT</td>
                        <td>TNRD-A</td>
                        <td>CAL</td>
                        <td>DMEM</td>
                        <td>AC</td>
                     </tr>
                     <tr>
                        <td>DU4475</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>WT</td>
                        <td>TNRD-A</td>
                        <td>NA</td>
                        <td>RPMI</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>EMG3</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>ND</td>
                        <td>TNRD-A</td>
                        <td>NA</td>
                        <td>DMEM</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>HCC1143</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>ND</td>
                        <td>TNRD-A</td>
                        <td>HCC</td>
                        <td>RPMI</td>
                        <td>DC</td>
                     </tr>
                     <tr>
                        <td>HCC1187</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>ND</td>
                        <td>TNRD-A</td>
                        <td>HCC</td>
                        <td>RPMI</td>
                        <td>DC</td>
                     </tr>
                     <tr>
                        <td>HCC1599</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>ND</td>
                        <td>TNRD-A</td>
                        <td>HCC</td>
                        <td>RPMI</td>
                        <td>DC</td>
                     </tr>
                     <tr>
                        <td>HCC1806</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>ND</td>
                        <td>TNRD-A</td>
                        <td>HCC</td>
                        <td>RPMI</td>
                        <td>SqC</td>
                     </tr>
                     <tr>
                        <td>HCC1937</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>MU</td>
                        <td>TNRD-A</td>
                        <td>HCC</td>
                        <td>RPMI</td>
                        <td>DC</td>
                     </tr>
                     <tr>
                        <td>HCC2157</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>ND</td>
                        <td>TNRD-A</td>
                        <td>HCC</td>
                        <td>RPMI</td>
                        <td>DC</td>
                     </tr>
                     <tr>
                        <td>HCC3153</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>MU</td>
                        <td>TNRD-A</td>
                        <td>HCC</td>
                        <td>RPMI</td>
                        <td>DC</td>
                     </tr>
                     <tr>
                        <td>HCC70</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>WT</td>
                        <td>TNRD-A</td>
                        <td>HCC</td>
                        <td>RPMI</td>
                        <td>DC</td>
                     </tr>
                     <tr>
                        <td>HMT3522</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>WT</td>
                        <td>TNRD-A</td>
                        <td>HMT</td>
                        <td>DMEM, F12</td>
                        <td>B</td>
                     </tr>
                     <tr>
                        <td>KPL-3C</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>ND</td>
                        <td>TNRD-A</td>
                        <td>KPL</td>
                        <td>RPMI</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>MA11</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>ND</td>
                        <td>TNRD-A</td>
                        <td>NA</td>
                        <td>DMEM</td>
                        <td>ILC</td>
                     </tr>
                     <tr>
                        <td>MDAMB435</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>WT</td>
                        <td>TNRD-A</td>
                        <td>MDA</td>
                        <td>DMEM</td>
                        <td>AC</td>
                     </tr>
                     <tr>
                        <td>MDAMB436</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>MU</td>
                        <td>TNRD-A</td>
                        <td>MDA</td>
                        <td>RPMI, L15</td>
                        <td>AC</td>
                     </tr>
                     <tr>
                        <td>MDAMB468</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>WT</td>
                        <td>TNRD-A</td>
                        <td>MDA</td>
                        <td>RPMI, L15</td>
                        <td>AC</td>
                     </tr>
                     <tr>
                        <td>MFM223</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>WT</td>
                        <td>TNRD-A</td>
                        <td>NA</td>
                        <td>MEM</td>
                        <td>C</td>
                     </tr>
                     <tr>
                        <td>SUM185PE</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>WT</td>
                        <td>TNRD-A</td>
                        <td>SUM</td>
                        <td>Ham's F12</td>
                        <td>DC</td>
                     </tr>
                     <tr>
                        <td>SUM229PE</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>WT</td>
                        <td>TNRD-A</td>
                        <td>SUM</td>
                        <td>RPMI</td>
                        <td>DC</td>
                     </tr>
                     <tr>
                        <td>BT549</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>WT</td>
                        <td>
                           <p>TNRD-B</p>
                           <p>TNRD-B</p>
                        </td>
                        <td>BT</td>
                        <td>RPMI</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>CAL120</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>WT</td>
                        <td>
                           <p>TNRD-B</p>
                           <p>TNRD-B</p>
                        </td>
                        <td>CAL</td>
                        <td>DMEM</td>
                        <td>AC</td>
                     </tr>
                     <tr>
                        <td>CAL51</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>WT</td>
                        <td>
                           <p>TNRD-B</p>
                           <p>TNRD-B</p>
                        </td>
                        <td>CAL</td>
                        <td>DMEM</td>
                        <td>AC</td>
                     </tr>
                     <tr>
                        <td>CAL851</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>WT</td>
                        <td>
                           <p>TNRD-B</p>
                           <p>TNRD-B</p>
                        </td>
                        <td>CAL</td>
                        <td>DMEM</td>
                        <td>AC</td>
                     </tr>
                     <tr>
                        <td>HCC1395</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>ND</td>
                        <td>
                           <p>TNRD-B</p>
                           <p>TNRD-B</p>
                        </td>
                        <td>HCC</td>
                        <td>RPMI</td>
                        <td>DC</td>
                     </tr>
                     <tr>
                        <td>HCC1739</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>ND</td>
                        <td>
                           <p>TNRD-B</p>
                           <p>TNRD-B</p>
                        </td>
                        <td>HCC</td>
                        <td>RPMI</td>
                        <td>DC</td>
                     </tr>
                     <tr>
                        <td>HCC38</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>ND</td>
                        <td>TNRD-B</td>
                        <td>HCC</td>
                        <td>RPMI</td>
                        <td>DC</td>
                     </tr>
                     <tr>
                        <td>HDQ-P1</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>MU</td>
                        <td>TNRD-B</td>
                        <td>NA</td>
                        <td>DMEM</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>Hs578T</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>WT</td>
                        <td>TNRD-B</td>
                        <td>NA</td>
                        <td>RPMI, DMEM</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>MDAMB157</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>WT</td>
                        <td>TNRD-B</td>
                        <td>MDA</td>
                        <td>RPMI, DMEM</td>
                        <td>MC</td>
                     </tr>
                     <tr>
                        <td>MDAMB231</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>WT</td>
                        <td>TNRD-B</td>
                        <td>MDA</td>
                        <td>RPMI, DMEM</td>
                        <td>AC</td>
                     </tr>
                     <tr>
                        <td>SKBR7</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>WT</td>
                        <td>TNRD-B</td>
                        <td>SKBR</td>
                        <td>RPMI</td>
                        <td>AC</td>
                     </tr>
                     <tr>
                        <td>SUM102PT</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>WT</td>
                        <td>TNRD-B</td>
                        <td>SUM</td>
                        <td>Ham's F12</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>SUM1315M02</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>MU</td>
                        <td>TNRD-B</td>
                        <td>SUM</td>
                        <td>Ham's F12</td>
                        <td>IDC</td>
                     </tr>
                     <tr>
                        <td>SUM149PT</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>MU</td>
                        <td>TNRD-B</td>
                        <td>SUM</td>
                        <td>Ham's F12</td>
                        <td>InfDC</td>
                     </tr>
                     <tr>
                        <td>SUM159PT</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>WT</td>
                        <td>TNRD-B</td>
                        <td>SUM</td>
                        <td>Ham's F12</td>
                        <td>AnC</td>
                     </tr>
                  </tbody>
               </table>
               <table-wrap-foot>
                  <p>Legend: SUBT – BC subtype, SER – CL series, MEDUM – growth medium used, TUM – type of source tumour, WT – wild type, UD – undetermined, LA – luminal A, LB – luminal B, H – HER2 positive, TNRD-A – triple negative A, TNRD-B – triple negative B, AC – adenocarcinoma, AnC – anaplastic carcinoma, B – benign tumour, C – carcinoma, CS – carcinosarcoma, DC – ductal carcinoma, IDC – invasive ductal carcinoma, ILC – invasive lobular carcinoma, InfC – inflammatory carcinoma, InfDC – inflammatory ductal carcinoma, MC – medullary carcinoma, SqC – squamous cell carcinoma, NA – no data available. Table 3 is a summary of Dai et al. (<xref ref-type="bibr" rid="b5">5</xref>), used with CC BY-NC 4.0 license.</p>
               </table-wrap-foot>
            </table-wrap>
         </sec>
         <sec id="s3.3" sec-type="Luminal breast cancer cell lines">
            <label>3.3</label>
            <title>Luminal breast cancer cell lines</title>
            <p>The luminal type of BC is characterised by the expression of ER+ and/or PR+. In the literature a systematic study on microRNA expression profiling (miRNAs) is described, that has unveiled distinctive over-expression of hsa-miR-501–5p, hsa-miR-202, hsa-miR-760 and hsa-miR-626 in luminal cell lines (LCLs), which are unique to LCLs without ERBB-2 expression (HER2-) and therefore helpful in specifying each CL subtype. Likewise, these miRNAs are associated with gene mutations of E-cadherin (a growth-suppressive effect) or with its loss. Therefore, LCLs are more differentiated and less prone to migration due to tight cell-cell junctions (<xref ref-type="bibr" rid="b25">25</xref>).</p>
            <p>Depending on the hormone receptor status and HER2 status, BC is divided into luminal A and luminal B, HER2+ and TNBC, which can be divided into basal, claudin-low, metaplastic and interferon-rich BC. Figure 1 a summary of Dai et al. (<xref ref-type="bibr" rid="b5">5</xref>) used with a CC BY-NC 4.0 license.</p>
            <p>Although in the literature, LCLs are often not further differentiated into subtypes A and B according to their HER2 status, this type of categorisation is important for uniform nomenclature, easier modelling, and when planning a response to tests of treatment. Type B LCLs are often more invasive and more aggressive than type A LCLs. It is reported in the literature that increased HER2 expression often correlates with decreased ER expression or with reduction of ER expression level (<xref ref-type="bibr" rid="b5">5</xref>).</p>
            <p>Patients with hormone-responsive BC receive hormone therapy (e.g. tamoxifen, letrozole, anastrozole, exemestane) and certain individuals receive chemotherapy (e.g. Adriamycin / cyclophosphamide; Adriamycin / cyclophosphamide / paclitaxel; docetaxel / cyclophosphamide) (<xref ref-type="bibr" rid="b26">26</xref>).</p>
         </sec>
         <sec id="s3.4" sec-type="HER2 + breast cancer cell lines">
            <label>3.4</label>
            <title>HER2 + breast cancer cell lines</title>
            <p>HER2+ CL (ER- and HER2+) often have characteristic changes in the chromosomal region 17q12, which includes the HER2, GRB7 (growth factor receptor-bound protein 7), PERLD1, STARD3, and C17ORF37 genes (<xref ref-type="bibr" rid="b27">27</xref>). Increased expression of these genes plays an important role in BC oncogenesis and appropriate treatment.</p>
            <p>The expression of miRNAs hsa-let-7b, hsa-miR-640, hsa-miR-200c, hsa-miR-378, hsa-miR-141, hsa-miR-196a, hsa-miR-29c and hsa-miR-18a, that are characteristic of CL with increased ERBB2 expression, is also increased (<xref ref-type="bibr" rid="b25">25</xref>).</p>
            <p>The literature mentions the importance of increased co-expression of HER2 genes STARD3, GRB7, PSMD3, and PERLD1, which allow the growth of cancer cells. The silencing of these genes allows for an additive decrease in cell viability as well as leads to induced apoptosis. A simultaneously targeted silencing of the target genes may increase the efficiency of the so-called anti-HER2 therapies and contradict transtuzumab resistance (<xref ref-type="bibr" rid="b28">28</xref>). Due to their properties, HER2+ CL are an intermediate point between LCL and BCL. They exhibit both luminal and basal CL properties. Based on the expression of luminal and basal markers other than ER and HER2, they can be further divided into luminal-ERBB2+ and ER-negative-ERBB2+ (<xref ref-type="bibr" rid="b25">25</xref>). Consistent with their molecular properties, cells of this subtype are more aggressive compared to LCL, since increased HER2 expression is associated with cell junction breakdown (<xref ref-type="bibr" rid="b25">25</xref>). Increased protein expression of the following proteins, estrogen receptor 1 (ESR1), mitogen-activated protein kinase 1 (MAPK1/3), mitogen-activated protein kinase kinase (MEK or MAPKK), tyrosine kinase 2 (TYK2), fatty acid synthase (FASN) and growth factor receptor-bound protein 7 (GRB7), is associated with increased sensitivity to transtuzumab (<xref ref-type="bibr" rid="b29">29</xref>). Increased expression of growth factor receptor-bound protein 2 (GRB2), retinoblastoma protein (RB1), and filamin A alpha (FLNA) indicates increased resistance to transtuzumab. Trastuzumab resistance may also be indicated by mitogen-activated protein kinase (MAPK), mammalian target of rapamycin (mTOR) and Toll-like receptor signalling pathways, as well as N-Glycan biosynthesis and inositol phosphate signalling (<xref ref-type="bibr" rid="b29">29</xref>).</p>
            <p>Standard pharmacological therapy for patients with HER2 positive BC is targeted in combination with chemotherapy (e.g. paclitaxel / trastuzumab; Adriamycin / cyclophosphamide / paclitaxel / trastuzumab +/- pertuzumab; docetaxel / carboplatin / trastuzumab ± pertuzumab), and in case it’s hormone receptor-positive, hormone therapy (tamoxifen, letrozole, anastrozole or exemestane) as well (<xref ref-type="bibr" rid="b26">26</xref>).</p>
         </sec>
         <sec id="s3.5" sec-type="TNBC cell lines">
            <label>3.5</label>
            <title>TNBC cell lines</title>
            <p>Of the CL subtypes, TNBC is the most heterogeneous. TNBC CLs have very low expression or are free of all three markers (ER-, PR-, HER2-). TNBC can be divided into two basal subtypes: TNBC-A and TNBC-B.</p>
            <p>TNBC-A lines are often referred to as basal-like because of the presence of:</p>
            <p>1.cytokeratins (KRT4/5/6A/6B/13/14/ 15/16/17),</p>
            <list>
               <list-item>
                  <label>2.</label>
                  <p>integrins (ITGA6, ITGB4/6) and</p>
               </list-item>
               <list-item>
                  <label>3.</label>
                  <p>LAMB3, LAMC2, TRIM29, S100A2, SLPI, ANXA8, COL17A1, BNC1, CD10/14/58/59, MET, LYN, CD133, GABRK, VTCN1, BST2, FABP7 (<xref ref-type="bibr" rid="b25">25</xref>).</p>
               </list-item>
            </list>
            <p>TNBC B CL is characterised by an increased expression of genes associated with aggressive and invasive properties: vimentin (VIM), moesin (MSN), plasminogen activator, tissue type (PLAT), transforming growth factor beta 1 (TGFB1), transforming growth factor beta-2 precursor (TGFBR2), tyrosine protein kinase receptor UFO (AXL), collagens (COL3A1, COL6A1/2/3, COL8A1), matrix metallopeptidase (MMP2/14), metallopeptidase inhibitor (TIMP1) and the like (<xref ref-type="bibr" rid="b5">5</xref>); and the characteristic of similarity between cancer stem cells such as CD44 (+) and CD24 (-) (<xref ref-type="bibr" rid="b29">29</xref>,<xref ref-type="bibr" rid="b30">30</xref>).</p>
            <p>Collagens (COL3A1, COL6A1/2/3, COL8A1), proteases (MMP2/14, TIMP1, CTSC, PLAU, PLAUR, SERPINE1/2, PLAT, uPA, PAi) and interactions between cytoskeletal stabilizing proteins (VIM, MSN) are important in remodelling the extracellular matrix responsible for cell migration. However, the signalling factors (TGFB1, TGFBR2, AXL) are crucial for the formation of aggressive morphology. Here certain proteins (EGFR, CAV1/2, MSN, ETS1) are also used to characterise TNBC CL (<xref ref-type="bibr" rid="b31">31</xref>,<xref ref-type="bibr" rid="b32">32</xref>).</p>
            <p>Specific miRNAs are used to define TNBC A and B CL. In type A, an increased expression of hsa-miR-492, hsa-miR-26b, hsa-miR-617 and hsa-miT-155 is mainly present. In type B, however, the expression of hsa-miR-22, hsa-532–3p, hsa-miR-125b, hsa-miR-501–5p, hsa-miR-155 is increased. Interestingly, hsa-miR-155 or miR-155–5p (TNBC-A) and hsa-miR-155 * or miR-155–3p (TNBC-B) originate from the same precursor, but exhibit a contradictory pattern of expression in these types of TNBC (<xref ref-type="bibr" rid="b25">25</xref>).</p>
            <p>The oncogenic role of hsa-miR-155 is well described in leukemias. It is also thought to play an important role in the cardiovascular system (defect leads to hypertension) and the immune response. Some of the proposed models of operation are in the context of apoptosis, differentiation, angiogenesis, proliferation, and epithelial-mesenchymal transition.</p>
            <p>Phenotypically, TNBC A cells are a more differentiated subtype than TRBC B and may have either luminal-like or basal-like morphological features. TNBC B cells have a more mesenchymal-like appearance and have a greater tendency to invade. Therefore, TNBC A CLs are mostly similar to the core basal tumour subtype. TNBC B cells can be used to model claudin-low or metaplastic BC (<xref ref-type="bibr" rid="b33">33</xref>).</p>
            <p>BRCA1 encodes a protein that forms the Rap80/Abraxas/BRCA1/Brcc36 complex in response to DNA damage. Mutations of this gene are associated with hereditary BC which also resembles sporadic core basal tumour. TNBC A CLs are characterized by a BRCA1 mutation pattern. Most of the currently available BC CLs (HCC1937, MDAMB436, SUM149PT, HCC3153) belong to this subtype (<xref ref-type="bibr" rid="b12">12</xref>,<xref ref-type="bibr" rid="b34">34</xref>).</p>
            <p>The standard pharmacological treatment for patients with TNBC is the use of chemotherapy (Adriamycin/cyclophosphamide; Adriamycin/cyclophosphamide/paclitaxel; docetaxel/cyclophosphamide) (<xref ref-type="bibr" rid="b26">26</xref>).</p>
         </sec>
         <sec id="s3.6" sec-type="Establishing breast cancer cell lines">
            <label>3.6</label>
            <title>Establishing breast cancer cell lines</title>
            <sec id="s3.6.1" sec-type="Isolation, establishment, and characterization">
               <label>3.6.1</label>
               <title>Isolation, establishment, and characterization</title>
               <p>After the removal of the tumour, the tissue is stored in a cell culture growth medium (e.g., Advanced DMEM/F12). If the tissue is being transported, the whole procedure should be carried out under cold conditions (on ice) at all times and as quickly as possible to minimize the time of cold ischemia. Cell isolation then begins. The whole process is performed in a sterile environment in a microbiological safety cabinet. Pieces of tissue are transferred to petri dishes and rinsed twice in PBS with added antibiotics (e.g. penicillin and streptomycin). PBS is again poured over the tissue, then pieces of dead tissue are removed. In a special petri dish, a mixture of active ingredients for enzymatic degradation (e.g. trypsin/EDTA) is prepared and pieces of tumour are placed therein. The mechanical and enzymatic treatment is followed by a selection of suitable cells for the next incubation/propagation step. The exact isolation protocol is described in more detail in the article by Gradišnik et al. (<xref ref-type="bibr" rid="b35">35</xref>).</p>
               <p>A few days after isolation, in the propagation stage, the cells begin to adhere to the surface. If most cells are still un-adhered, the entire cell suspension from individual vessels is centrifuged at 1400 rpm for 5 minutes, and fresh medium with serum (e.g. 5 % fetal bovine serum) is added to the cell sedimentation and returned to the vessels. In this way, the medium is changed every second or third day until most cells are adherent. A week or two (depending on the cell type) after the isolation, different cell types adhere to the surface, thus establishing the primary culture, which is then frozen. Part of the primary cell culture is further cultivated to obtain pure CL. All other cell types (e.g. fibroblasts) must be removed from the cell culture. Several approaches may be used for further work until the morphologically epithelial type of cells prevails.</p>
               <p>The determination of CL properties is done in many different ways and by different methods, and is called the characterization process. The most commonly used methods are: morphological analysis, karyotyping, STR profiling, gene expression, immunohistochemistry and / or immunocytochemistry, and functional assays (<xref ref-type="bibr" rid="b36">36</xref>).</p>
            </sec>
            <sec id="s3.6.2" sec-type="Mutations">
               <label>3.6.2</label>
               <title>Mutations</title>
               <p>The occurrence of DNA alterations is greater in BC CL than in tumours. On average, CL alterations are twice as frequent as in tumours (<xref ref-type="bibr" rid="b5">5</xref>,<xref ref-type="bibr" rid="b37">37</xref>). This may be due to the fact that CLs are mostly derived from high-grade invasive tumours. In such cells, genomic changes occur more rapidly in the <italic>in vitro</italic> cultivation process. For this reason BC CLs have changes in the DNA that are not present in the original tissue and are merely the result of cultivation. Such <italic>de novo</italic> mutations can lead to phenotypic changes. An example is MCF-7 CL, which has variable sensitivity to tamoxifen (<xref ref-type="bibr" rid="b38">38</xref>). Nevertheless, on the basis of comparative genomic hybridization (CGH) data, CLs are considered to be comparable to the original tissue in terms of the major or more significant changes in the DNA (5: 37–39).</p>
               <p>There is another type of carcinogenic factor influencing the expression patterns of a whole range of genes. These factors alter the expression of certain critical genes (and the formation and function of their products) without directly affecting the DNA sequence. This is known as epigenetics. For both epigenetic and genetic alterations, a new pattern is required to be imprinted in newly created cellular memory and transferred to subsequent generations of cells (<xref ref-type="bibr" rid="b40">40</xref>). These mechanisms are also similar between BC CL and tumours. Literature describes that methylation patterns of CpG islands were comparable between CL and tumour. The genes with a methylation pattern present in the promoter region were: ER, PR, HIC1 protein (Hypermethylated in cancer 1), APC protein (adenomatous polyposis coli), breast cancer 1 (BRCA1) and the like. In addition, mismatches on other genes have been reported (<xref ref-type="bibr" rid="b41">41</xref>).</p>
               <p>It is clear from the literature that, at the molecular level, discriminatory markers and the consequent phenotypic features present in CL are often also characteristic of tumour tissue. E.g. genes that correlate with the ER+ or ER- phenotype in BC CL are associated with a positive or negative correlation of ER expression in tumour tissue (<xref ref-type="bibr" rid="b5">5</xref>).</p>
            </sec>
            <sec id="s3.6.3" sec-type="Cellular environment">
               <label>3.6.3</label>
               <title>Cellular environment</title>
               <p>The cellular environment is influenced by several factors; growth medium, cultivation parameters (temperature, atmosphere, etc.), growth in 2D or 3D cultures, or as xenograft and added growth factors.</p>
               <p>Complex intercellular communications are lost in the <italic>in vivo</italic> environment when CLs are grown in plastic vessels and in two dimensions. CLs are sensitive to culture conditions. This is especially true for the addition of growth factors that can alter the cellular phenotype and lead to inappropriate activation of signalling pathways or differentiation. Growing in an inappropriate environment can drastically affect cell morphology, cell-cell and cell-matrix interactions, cell polarity and differentiation, as well as alter signalling cascades of gene expression (<xref ref-type="bibr" rid="b42">42</xref>).</p>
               <p>Identifying optimal conditions for cell growth and cultivation of a specific phenotype is of paramount importance. As a model, 2D cultures have many drawbacks, especially when compared to 3D systems (e.g. organoids or 3D-printed models). 2D and 3D cultures are also used to study the activity of active substances. Not surprisingly, tumour cells in 3D cultures are more resilient or less sensitive to the active substances compared to cells in 2D cultures (<xref ref-type="bibr" rid="b42">42</xref>). This may be due to reduced access to the ingredients of the active substance in the medium, pathophysiological differences resulting from hypoxia in 3D cultures, or changes in the cell cycle. Also described is the significance of unstable conditions that occur in the <italic>in vitro</italic> environment (e.g., the so-called <italic>de novo</italic> mutations). Of importance are also cultivation methods, which have a significant effect on cellular metabolic activity, cellular proliferation and, ultimately, cellular sensitivity to the active substance. Among 2D, 3D, and spheroid CL models, only 3D cell cultures have been shown to exhibit comparable cell density as natural tissue and also a comparable drug response as a solid tumour (<xref ref-type="bibr" rid="b42">42</xref>,<xref ref-type="bibr" rid="b43">43</xref>).</p>
               <p>Interactions between cells and the extracellular matrix play an important role in the mechanisms of cancer cell resistance to drugs. Cells that are cultivated in a 3D silk assembly, which has a similar interconnection, orientation, and size of fibre to the extracellular matrix of tumour tissue, are more resistant to paclitaxel (<xref ref-type="bibr" rid="b44">44</xref>). Changes in the architecture of the artificial extracellular matrix have been linked to the progression of cancer. In this context, 3D systems could allow inappropriate dosage of the active substance in the clinical setting to be avoided in cases of resistance (<xref ref-type="bibr" rid="b42">42</xref>).</p>
            </sec>
         </sec>
         <sec id="s3.7" sec-type="Limitations and dilemmas of in vitro use of CL">
            <label>3.7</label>
            <title>Limitations and dilemmas of in vitro use of CL</title>
            <p>Despite the important role played by BC CL in the process of exploring and discovering mechanisms of tumour initiation and evolution, they also have their drawbacks.</p>
            <p>It is necessary to emphasize the dilemma of the transferability of CL findings to the clinical setting (<xref ref-type="bibr" rid="b45">45</xref>). Although the major proportion of tissues is identical in terms of the main determination of receptor and HER2 status, there has recently been a growing awareness of subsequent drastic genetic and epigenetic changes as part of cell line cultivation in a laboratory setting. Therefore, the question of the comparability of molecular characteristics, heterogeneity of BC and CL (<xref ref-type="bibr" rid="b5">5</xref>,<xref ref-type="bibr" rid="b45">45</xref>) remains open. The clonal population of a single CL is unable to fully demonstrate the diversity of processes at the intra-tumoral level. Carcinogenesis is a multi-stage process that involves many clinical and pathological stages. These include typical hyperproliferation, local invasion, invasive carcinoma formation, and ultimately, spreading of the disease. This process is accompanied by the gradual acquisition of various types of genetic and epigenetic cell mutations, followed by clonal selection and expansion.</p>
            <p>During the CL cultivation phase, certain types of cells may be eliminated, which are initially present in the tissue but cannot develop due to environmental factors. This may be due to a broken microenvironment or a lack of specific factors. Therefore, their collapse may occur, thereby altering tumour heterogeneity. An example of this is cells that do not grow on a plastic surface or do not grow at all or they cannot thrive without the addition of specific factors from the tumour microenvironment, so they die. Therefore, the question arises as to whether a potential CL that could serve as a tumour model while maintaining all heterogeneity is possible at all.</p>
            <p>Success in long-term propagation is an important limiting factor in producing quality CL. TNBC CL is an example of this. This cancer subtype has at least 4 subtypes: core basal, claudin-low, metaplastic, and interferon-rich. Each of these has important molecular characteristics and clinical implications. Only TNBC A and TNBC B lines are available. TNBC A is generally well representative of the core basal subtype, and TNBC B is useful for modelling the claudin-low and/or metaplastic subtype. However, there is a deficiency for the subtype interferon-rich subtype. There are also very few CLs (e.g. MCF7, T-47D, MDAMB231), despite the total number, that have established themselves in the market. Given the technical difficulties in extracting viable tumour tissue from the surrounding stroma, most BCs are originally from invasive carcinoma tissue, leading us to consider the representativeness of the original tissue. Such an example is reported in the literature for the MDAMB435 CL, of which the original tissue may have been in fact occult melanoma (<xref ref-type="bibr" rid="b46">46</xref>).</p>
            <p>The literature also describes the effects of fibroblasts on the morphological changes of CL. The effect of fibroblasts on the stimulation of luminal keratin expression in basal cells and basal keratins in luminal cells was described. Also described was that cells that were cultivated in an environment with high/low EGFR activity often become ER+/−. This suggests the importance of environmental impact in CL cultivation (<xref ref-type="bibr" rid="b47">47</xref>). An additional consideration when using BC CL is the reproducibility in different laboratories or in different conditions. In these cases, CLs may develop different properties. There are prominent examples in the literature of different categoriation of the same CL into unique groups based on a different molecular and morphological description.</p>
            <p>A review of these anomalies was described by Dai et al. (<xref ref-type="bibr" rid="b5">5</xref>). The examples they highlighted are relevant to HER2 and ER status. These anomalies are shown in <xref ref-type="table" rid="table4">Table 4</xref>.</p>
            <table-wrap position="anchor" id="table4">
               <label>Table 4:</label>
               <caption>
                  <p> Eight cell lines that are defined differently by the literature regarding receptor status.</p>
               </caption>
               <table>
                  <colgroup>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th>Cell lines</th>
                        <th>ER</th>
                        <th>PR</th>
                        <th>HER2</th>
                        <th>Subtype</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td>HCC1007</td>
                        <td>+</td>
                        <td>-</td>
                        <td>-</td>
                        <td>LA</td>
                     </tr>
                     <tr>
                        <td>HCC1007</td>
                        <td>+</td>
                        <td>-</td>
                        <td>+</td>
                        <td>LB</td>
                     </tr>
                     <tr>
                        <td>HCC1007</td>
                        <td>-</td>
                        <td>-</td>
                        <td>+</td>
                        <td>HER2+</td>
                     </tr>
                     <tr>
                        <td>HCC1419</td>
                        <td>+</td>
                        <td>-</td>
                        <td>+</td>
                        <td>LB</td>
                     </tr>
                     <tr>
                        <td>HCC1419</td>
                        <td>-</td>
                        <td>-</td>
                        <td>+</td>
                        <td>HER2+</td>
                     </tr>
                     <tr>
                        <td>HCC1500</td>
                        <td>+</td>
                        <td>+</td>
                        <td>-</td>
                        <td>LA</td>
                     </tr>
                     <tr>
                        <td>HCC1500</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>TNRD-B</td>
                     </tr>
                     <tr>
                        <td>HCC2185</td>
                        <td>-</td>
                        <td>-</td>
                        <td>-</td>
                        <td>TNRD-A</td>
                     </tr>
                     <tr>
                        <td>HCC2185</td>
                        <td>-</td>
                        <td>-</td>
                        <td>+</td>
                        <td>HER2+</td>
                     </tr>
                     <tr>
                        <td>SUM52PE</td>
                        <td>+</td>
                        <td>-</td>
                        <td>+</td>
                        <td>LB</td>
                     </tr>
                     <tr>
                        <td>SUM52PE</td>
                        <td>+</td>
                        <td>-</td>
                        <td>-</td>
                        <td>LA</td>
                     </tr>
                     <tr>
                        <td>SUM44PE</td>
                        <td>+</td>
                        <td>+</td>
                        <td>+</td>
                        <td>LB</td>
                     </tr>
                     <tr>
                        <td>SUM44PE</td>
                        <td>+</td>
                        <td>+/-</td>
                        <td>-</td>
                        <td>LA</td>
                     </tr>
                     <tr>
                        <td>EVSA-T</td>
                        <td>-</td>
                        <td>-</td>
                        <td>+</td>
                        <td>HER2+</td>
                     </tr>
                     <tr>
                        <td>EVSA-T</td>
                        <td>-</td>
                        <td>+</td>
                        <td>-</td>
                        <td>LA</td>
                     </tr>
                     <tr>
                        <td>MPE600</td>
                        <td>+</td>
                        <td>-</td>
                        <td>-</td>
                        <td>LA</td>
                     </tr>
                     <tr>
                        <td>MPE600</td>
                        <td>+</td>
                        <td>-</td>
                        <td>+</td>
                        <td>LB</td>
                     </tr>
                  </tbody>
               </table>
               <table-wrap-foot>
                  <p>Legend: LA - luminal type A, LB - luminal type B, HER2+, TNBC A - triple-negative breast cancer type A, TNBC B - triple-negative breast cancer type B. Table 4 is a summary of Table 3 of Dai and barrel (<xref ref-type="bibr" rid="b5">5</xref>) used with CC BY-NC 4.0 license..</p>
               </table-wrap-foot>
            </table-wrap>
            <p>Therefore, research based on CL and their comparisons is challenging. Also, the understanding of CL is poor and inconsistent.</p>
            <p>It should be noted that a large proportion of the research was performed in a 2D environment rather than a 3D environment, which is a better approximation to physiological tissue. In most experiments on CL in a 2D environment, cells are cultivated on rigid materials such as polyester or glass. Such standard rudimentary cell monolayer cultures present a less real image of the actual tissue’s physiology. The selection of material and culture conditions significantly influences tissue-specific architecture (polarity, flattened cell shape), mechanical/biochemical signals, and therefore intercellular communication (<xref ref-type="bibr" rid="b48">48</xref>). A comparison between the general features of a 2D and a 3D system is presented in <xref ref-type="table" rid="table5">Table 5</xref>.</p>
         </sec>
      </sec>
      <sec id="s4" sec-type="Discussion">
         <label>4</label>
         <title>Discussion</title>
         <p>With the advancement of high-throughput technology in molecular genetics, the amount of information in various fields of genomics, understanding of transcription mechanisms, translation, and epigenetic mechanisms has increased immensely and became accessible for cancer research. The aim is to integrate information on many levels to understand the major functional differences responsible for cancer heterogeneity. This could allow the development of new therapeutic approaches. As part of this, there are two major trends; broadening the spectrum and the number of subtypes that are very specific, while looking for common points and characteristics of subtypes.</p>
         <p>
            <xref ref-type="table" rid="table5">Table 5</xref> is a summary of <xref ref-type="table" rid="table1">Table 1</xref> from Hoarau-Vécho et al. (<xref ref-type="bibr" rid="b48">48</xref>) used with CC BY-NC 4.0 license.</p>
         <table-wrap position="anchor" id="table5">
            <label>Table 5:</label>
            <caption>
               <p> Comparison between 2D and 3D cell cultures.</p>
            </caption>
            <table>
               <colgroup>
                  <col/>
                  <col/>
                  <col/>
               </colgroup>
               <thead>
                  <tr>
                     <th>Criteria</th>
                     <th>2D</th>
                     <th>3D</th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td>Morphology</td>
                     <td>
                        <p>Shape changed</p>
                        <p>Polarization lost</p>
                     </td>
                     <td>
                        <p>Real shape</p>
                        <p>Polarization conserved</p>
                     </td>
                  </tr>
                  <tr>
                     <td>Genetic profile</td>
                     <td>Cellular adhesion, proliferation and survival genes are modified compared to <italic>in vivo</italic>
                     </td>
                     <td>Better representation of growth factors, pro-angiogenic and adhesion molecule genes</td>
                  </tr>
                  <tr>
                     <td>
                        <p>Cell differentiation</p>
                        <p>Morphogenesis</p>
                     </td>
                     <td>Non spontaneous</td>
                     <td>Could be spontaneous via cellular contact or soluble factors</td>
                  </tr>
                  <tr>
                     <td>Angiogenesis</td>
                     <td>Only observational</td>
                     <td>Can be functional</td>
                  </tr>
                  <tr>
                     <td>Mathematical model</td>
                     <td>Possible</td>
                     <td>Better geometry, better link between structure and function</td>
                  </tr>
                  <tr>
                     <td>Reproducibility</td>
                     <td>Short term only</td>
                     <td>Controversial</td>
                  </tr>
                  <tr>
                     <td>Costs</td>
                     <td>Affordable</td>
                     <td>Expensive</td>
                  </tr>
                  <tr>
                     <td>Multicellular study</td>
                     <td>Better for determining the immune response</td>
                     <td>Good in co-culture. Implementation demanding for a larger number.</td>
                  </tr>
               </tbody>
            </table>
            <table-wrap-foot>
               <p>Table 5 is a summary of Hoarau-Vécho et al. (<xref ref-type="bibr" rid="b48">48</xref>), used with CC BY-NC 4.0 license.</p>
            </table-wrap-foot>
         </table-wrap>
         <p>As for the molecular divisions of the BC subtypes, Sørlie et al. set the standard for intrinsic categorisation. For information purposes, it is nevertheless possible to find examples of different definitions in the literature (<xref ref-type="bibr" rid="b10">10</xref>-<xref ref-type="bibr" rid="b12">12</xref>). In a study by Sotiriou et al. 6 subtypes within the BC group were described using 706 cDNA fragments. These groups were three luminal-like subtypes, one HER2-like and two basal-like subtypes (<xref ref-type="bibr" rid="b49">49</xref>). Other examples are the division of Fana et al. (use of 70 gene signatures) into 4 subtypes lacking the normal-like subtype (LA, LB, HER2 overexpression, basal) (<xref ref-type="bibr" rid="b50">50</xref>); in the study by Lehmann et al. TNBC was divided into 6 groups (two basal-like (BL1 and BL2), one immunomodulatory (IM), one mesenchymal (M), one mesenchymal stem-like (MSL), and one luminal androgen receptor (LAR) subtype (<xref ref-type="bibr" rid="b51">51</xref>).</p>
         <p>It should also be mentioned that the comparability of research and results on BC CL is more difficult because of the large number of studies and agreeing to a single name. In his article Dai et al. cites a number of studies: Charafe-Jauffret et al. (<xref ref-type="bibr" rid="b31">31</xref>), Riaz et al. (<xref ref-type="bibr" rid="b25">25</xref>), Lehmann et al. (<xref ref-type="bibr" rid="b51">51</xref>) all used different classifications (<xref ref-type="bibr" rid="b5">5</xref>). In addition to the different classifications, there are also differences in molecular characterization. A number of authors have also referred to the problem of excessive and non-standardized, uncontrolled use of CL (<xref ref-type="bibr" rid="b52">52</xref>) and the dilemma of the transferability of CL findings to the clinical setting (<xref ref-type="bibr" rid="b45">45</xref>,<xref ref-type="bibr" rid="b53">53</xref>). Although the tissues in the majority are identical in terms of the main determination of receptor status and HER2 status, there has recently been a growing awareness of subsequent drastic genetic and epigenetic changes in CL cultivation in a laboratory setting. Therefore, the question of the comparability of molecular characteristics, heterogeneity of BC and CL (<xref ref-type="bibr" rid="b5">5</xref>,<xref ref-type="bibr" rid="b45">45</xref>) remains open. The clonal population of a single CL cannot fully demonstrate the diversity of processes at the level within the tumour. Carcinogenesis is a multi-stage process that involves many clinical and pathological stages. These include typical hyperproliferation, local invasion, invasive carcinoma formation, and ultimately, spreading of the disease. This process is accompanied by the gradual acquisition of various types of genetic and epigenetic cell mutations, followed by clonal selection and expansion. This process is accompanied by the gradual acquisition of various types of genetic and epigenetic cell mutations, followed by clonal selection and expansion. During the CL cultivation phase, certain types of cells may be eliminated, which are initially present in the tissue but cannot develop due to environmental factors. This may be due to a broken microenvironment or a lack of specific factors. Therefore, their collapse may occur, thereby altering tumour heterogeneity. An example of this are cells that do not grow on a plastic surface or do not grow at all or they cannot thrive without the addition of specific factors from the tumour microenvironment, so they die. Therefore, the question arises as to whether a potential CL that could serve as a tumour model while maintaining all heterogeneity is possible at all. They also mentioned the problem of contamination. There are several sources of CL contamination: low-quality manner of cultivating CL, inadequate quality control, user error in sample labeling, aerosol cell transfer, etc. (<xref ref-type="bibr" rid="b52">52</xref>,<xref ref-type="bibr" rid="b54">54</xref>-<xref ref-type="bibr" rid="b56">56</xref>).</p>
         <p>Concerns and choice of type (2D or 3D, <italic>in vitro</italic> or <italic>in </italic>
            <italic>vivo</italic>) of CL cultivation depends on the primary purpose of the study. At the same time, it is necessary to be aware of the advantages and disadvantages of the different methods described in the article. Despite certain shortcomings, the fact remains that CLs are of paramount importance for the study of carcinogenesis as well as new kinds of treatments. In addition, standardized validation of CL (<xref ref-type="bibr" rid="b53">53</xref>) is essential to ensure the integrity of research. It is recommended that your samples be inspected and checked for cross contamination and authenticity before use. Derivation of new CLs should accompany the determination of genetic ancestry to the primary tissue by STR profiling of the primary tissue and CL gene code. Histological and phenotypic markers should also be examined for characterization and comparison.</p>
         <p>The field of CL cultivation is developing rapidly. It is reasonable to assume that the more recent research methods (molecular genetics, proteomics, etc.) will be able to better define the nature of BC.</p>
      </sec>
   </body>
   <back>
      <ack>
         <label>5</label>
         <title>Acknowledgement</title>
         <p>We, the authors, thank the Slovenian Research Agency (contracts: P3–0036, I0–0029 and J3–9272) and the University Medical Centre Maribor (contract: IRP 2018 / 01–10) for co-financing research.</p>
      </ack>
      <ref-list>
         <ref id="b1">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Ferlay</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Soerjomataram</surname>
                     <given-names>I</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Dikshit</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Eser</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mathers</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rebelo</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012</article-title>. 
                    <source>Int J Cancer</source>. 
                    <year>2015</year>
                    <month>Mar</month>;
                    <volume>136</volume>(
                    <issue>5</issue>):
                    <fpage>E359</fpage>–
                    <lpage>86</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/ijc.29210</pub-id>
                    <pub-id pub-id-type="pmid">25220842</pub-id>
                    <issn>0020-7136</issn>
                </mixed-citation>
         </ref>
         <ref id="b2">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Zadnik</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Primic Zakelj</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lokar</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Jarm</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ivanus</surname>
                     <given-names>U</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zagar</surname>
                     <given-names>T</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Cancer burden in slovenia with the time trends analysis</article-title>. 
                    <source>Radiol Oncol</source>. 
                    <year>2017</year>
                    <month>Feb</month>;
                    <volume>51</volume>(
                    <issue>1</issue>):
                    <fpage>47</fpage>–
                    <lpage>55</lpage>. 
                    <pub-id pub-id-type="doi">10.1515/raon-2017-0008</pub-id>
                    <pub-id pub-id-type="pmid">28265232</pub-id>
                    <issn>1318-2099</issn>
                </mixed-citation>
         </ref>
         <ref id="b3">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Dawood</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Broglio</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Buzdar</surname>
                     <given-names>AU</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hortobagyi</surname>
                     <given-names>GN</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Giordano</surname>
                     <given-names>SH</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review</article-title>. 
                    <source>J Clin Oncol</source>. 
                    <year>2010</year>
                    <month>Jan</month>;
                    <volume>28</volume>(
                    <issue>1</issue>):
                    <fpage>92</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1200/JCO.2008.19.9844</pub-id>
                    <pub-id pub-id-type="pmid">19933921</pub-id>
                    <issn>0732-183X</issn>
                </mixed-citation>
         </ref>
         <ref id="b4">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Brenton</surname>
                     <given-names>JD</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Carey</surname>
                     <given-names>LA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ahmed</surname>
                     <given-names>AA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Caldas</surname>
                     <given-names>C</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Molecular classification and molecular forecasting of breast cancer: ready for clinical application?</article-title>
                    <source>J Clin Oncol</source>. 
                    <year>2005</year>
                    <month>Oct</month>;
                    <volume>23</volume>(
                    <issue>29</issue>):
                    <fpage>7350</fpage>–
                    <lpage>60</lpage>. 
                    <pub-id pub-id-type="doi">10.1200/JCO.2005.03.3845</pub-id>
                    <pub-id pub-id-type="pmid">16145060</pub-id>
                    <issn>0732-183X</issn>
                </mixed-citation>
         </ref>
         <ref id="b5">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Dai</surname>
                     <given-names>X</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Cheng</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bai</surname>
                     <given-names>Z</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Li</surname>
                     <given-names>J</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Breast cancer cell line classification and its relevance with breast tumor subtyping</article-title>. 
                    <source>J Cancer</source>. 
                    <year>2017</year>
                    <month>Sep</month>;
                    <volume>8</volume>(
                    <issue>16</issue>):
                    <fpage>3131</fpage>–
                    <lpage>41</lpage>. 
                    <pub-id pub-id-type="doi">10.7150/jca.18457</pub-id>
                    <pub-id pub-id-type="pmid">29158785</pub-id>
                    <issn>0378-2360</issn>
                </mixed-citation>
         </ref>
         <ref id="b6">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Cope</surname>
                     <given-names>LM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Fackler</surname>
                     <given-names>MJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lopez-Bujanda</surname>
                     <given-names>Z</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wolff</surname>
                     <given-names>AC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Visvanathan</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gray</surname>
                     <given-names>JW</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Do breast cancer cell lines provide a relevant model of the patient tumor methylome?</article-title>.
                    <source>PLoS One</source>. 
                    <year>2014</year>; 
                    <volume>9</volume>(
                    <issue>8</issue>):
                    <fpage>e105545</fpage>. 
                    <pub-id pub-id-type="doi">10.1371/journal.pone.0105545</pub-id> 
                    <pub-id pub-id-type="pmid">25157401</pub-id>
                    <issn>1932-6203</issn> 
                </mixed-citation>
         </ref>
         <ref id="b7">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Chavez</surname>
                     <given-names>KJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Garimella</surname>
                     <given-names>SV</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lipkowitz</surname>
                     <given-names>S</given-names>
                  </name>
                    </person-group>.
                    <article-title>Triple negative breast cancer cell lines: One tool in the search for better treatment of triple negative breast cancer</article-title>.
                    <source>Breast Dis</source>. 
                    <year>2010</year>; 
                    <volume>32</volume>(
                    <issue>1-2</issue>):
                    <fpage>35</fpage>-
                    <lpage>48</lpage>.
                    <pub-id pub-id-type="doi">doi: 10.1371/journal.pone.0105545</pub-id> 
                    <pub-id pub-id-type="pmid">25157401</pub-id>
                    <issn>1932-6203</issn> 
                </mixed-citation>
         </ref>
         <ref id="b8">
            <mixed-citation publication-type="book-chapter">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Ellis</surname>
                     <given-names>IO</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Collins</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ichihara</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>MacGrogan</surname>
                     <given-names>G</given-names>
                  </name>
                    </person-group>. 
                    <chapter-title>Invasive carcinoma of no special type</chapter-title>. In: 
                    <person-group person-group-type="editor">
                        <name name-style="western">
                     <surname>Lakhani</surname>
                     <given-names>SR</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Elis</surname>
                     <given-names>IO</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Schnitt</surname>
                     <given-names>SJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Tan</surname>
                     <given-names>PH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Vijver</surname>
                     <given-names>MJ</given-names>
                  </name>, 
                        <role>eds</role>
                    </person-group>. 
                    <source>WHO classification of Tumours of the Breast</source>. 
                    <publisher-loc>Lyon</publisher-loc>: 
                    <publisher-name>IARC</publisher-name>; 
                    <year>2012</year>.
                </mixed-citation>
         </ref>
         <ref id="b9">
            <mixed-citation publication-type="book-chapter">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Lakhani</surname>
                     <given-names>SR</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rakha</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Simpson</surname>
                     <given-names>PT</given-names>
                  </name>
                    </person-group>. 
                    <chapter-title>Special subtypes</chapter-title>. In: 
                    <person-group person-group-type="editor">
                        <name name-style="western">
                     <surname>Lakhani</surname>
                     <given-names>SR</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Elis</surname>
                     <given-names>IO</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Schnitt</surname>
                     <given-names>SJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Tan</surname>
                     <given-names>PH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Vijver</surname>
                     <given-names>MJ</given-names>
                  </name>, 
                        <role>eds</role>
                    </person-group>. 
                    <source>WHO classification of tumours of the breast</source>. 
                    <publisher-loc>Lyon</publisher-loc>: 
                    <publisher-name>IARC</publisher-name>; 
                    <year>2012</year>.
                </mixed-citation>
         </ref>
         <ref id="b10">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Perou</surname>
                     <given-names>CM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sorlie</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Eisen</surname>
                     <given-names>MB</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>van de Rijn</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Jeffrey</surname>
                     <given-names>SS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rees</surname>
                     <given-names>CA</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Molecular portraits of human breast tumours</article-title>. 
                    <source>Nature</source>. 
                    <year>2000</year>
                    <month>Aug</month>;
                    <volume>406</volume>(
                    <issue>6797</issue>):
                    <fpage>747</fpage>–
                    <lpage>52</lpage>. 
                    <pub-id pub-id-type="doi">10.1038/35021093</pub-id>
                    <pub-id pub-id-type="pmid">10963602</pub-id>
                    <issn>0028-0836</issn>
                </mixed-citation>
         </ref>
         <ref id="b11">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Sorlie</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Perou</surname>
                     <given-names>CM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Tibshirani</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Aas</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Geisler</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Johnsen</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications</article-title>. 
                    <source>Proc Natl Acad Sci USA</source>. 
                    <year>2001</year>
                    <month>Sep</month>;
                    <volume>98</volume>(
                    <issue>19</issue>):
                    <fpage>10869</fpage>–
                    <lpage>74</lpage>. 
                    <pub-id pub-id-type="doi">10.1073/pnas.191367098</pub-id>
                    <pub-id pub-id-type="pmid">11553815</pub-id>
                    <issn>0027-8424</issn>
                </mixed-citation>
         </ref>
         <ref id="b12">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Sorlie</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Tibshirani</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Parker</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hastie</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Marron</surname>
                     <given-names>JS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Nobel</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Repeated observation of breast tumor subtypes in independent gene expression data sets</article-title>. 
                    <source>Proc Natl Acad Sci USA</source>. 
                    <year>2003</year>
                    <month>Jul</month>;
                    <volume>100</volume>(
                    <issue>14</issue>):
                    <fpage>8418</fpage>–
                    <lpage>23</lpage>. 
                    <pub-id pub-id-type="doi">10.1073/pnas.0932692100</pub-id>
                    <pub-id pub-id-type="pmid">12829800</pub-id>
                    <issn>0027-8424</issn>
                </mixed-citation>
         </ref>
         <ref id="b13">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Cheang</surname>
                     <given-names>MC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Chia</surname>
                     <given-names>SK</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Voduc</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gao</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Leung</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Snider</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer</article-title>. 
                    <source>J Natl Cancer Inst</source>. 
                    <year>2009</year>
                    <month>May</month>;
                    <volume>101</volume>(
                    <issue>10</issue>):
                    <fpage>736</fpage>–
                    <lpage>50</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/jnci/djp082</pub-id>
                    <pub-id pub-id-type="pmid">19436038</pub-id>
                    <issn>0027-8874</issn>
                </mixed-citation>
         </ref>
         <ref id="b14">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Smid</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wang</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zhang</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sieuwerts</surname>
                     <given-names>AM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Yu</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Klijn</surname>
                     <given-names>JG</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Subtypes of breast cancer show preferential site of relapse</article-title>. 
                    <source>Cancer Res</source>. 
                    <year>2008</year>
                    <month>May</month>;
                    <volume>68</volume>(
                    <issue>9</issue>):
                    <fpage>3108</fpage>–
                    <lpage>14</lpage>. 
                    <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-5644</pub-id>
                    <pub-id pub-id-type="pmid">18451135</pub-id>
                    <issn>0008-5472</issn>
                </mixed-citation>
         </ref>
         <ref id="b15">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Dai</surname>
                     <given-names>X</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Li</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bai</surname>
                     <given-names>Z</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Yang</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Liu</surname>
                     <given-names>X</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zhan</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Breast cancer intrinsic subtype classification, clinical use and future trends</article-title>. 
                    <source>Am J Cancer Res</source>. 
                    <year>2015</year>
                    <month>Sep</month>;
                    <volume>5</volume>(
                    <issue>10</issue>):
                    <fpage>2929</fpage>–
                    <lpage>43</lpage>.
                    <pub-id pub-id-type="pmid">26693050</pub-id>
                    <issn>2156-6976</issn>
                </mixed-citation>
         </ref>
         <ref id="b16">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Hole</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Pedersen</surname>
                     <given-names>AM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hansen</surname>
                     <given-names>SK</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lundqvist</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Yde</surname>
                     <given-names>CW</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lykkesfeldt</surname>
                     <given-names>AE</given-names>
                  </name>
                    </person-group>. 
                    <article-title>New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane</article-title>. 
                    <source>Int J Oncol</source>. 
                    <year>2015</year>
                    <month>Apr</month>;
                    <volume>46</volume>(
                    <issue>4</issue>):
                    <fpage>1481</fpage>–
                    <lpage>90</lpage>. 
                    <pub-id pub-id-type="doi">10.3892/ijo.2015.2850</pub-id>
                    <pub-id pub-id-type="pmid">25625755</pub-id>
                    <issn>1019-6439</issn>
                </mixed-citation>
         </ref>
         <ref id="b17">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Holen</surname>
                     <given-names>I</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Speirs</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Morrissey</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Blyth</surname>
                     <given-names>K</given-names>
                  </name>
                    </person-group>. 
                    <article-title>
                        <italic toggle="yes">In vivo</italic> models in breast cancer research: progress, challenges and future directions </article-title>. 
                    <source>Dis Model Mech</source>. 
                    <year>2017</year>
                    <month>Apr</month>;
                    <volume>10</volume>(
                    <issue>4</issue>):
                    <fpage>359</fpage>–
                    <lpage>71</lpage>. 
                    <pub-id pub-id-type="doi">10.1242/dmm.028274</pub-id>
                    <pub-id pub-id-type="pmid">28381598</pub-id>
                    <issn>1754-8403</issn>
                </mixed-citation>
         </ref>
         <ref id="b18">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Holliday</surname>
                     <given-names>DL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Speirs</surname>
                     <given-names>V</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Choosing the right cell line for breast cancer research</article-title>. 
                    <source>Breast Cancer Res</source>. 
                    <year>2011</year>
                    <month>Aug</month>;
                    <volume>13</volume>(
                    <issue>4</issue>):
                    <fpage>215</fpage>. 
                    <pub-id pub-id-type="doi">10.1186/bcr2889</pub-id>
                    <pub-id pub-id-type="pmid">21884641</pub-id>
                    <issn>1465-5411</issn>
                </mixed-citation>
         </ref>
         <ref id="b19">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Greely</surname>
                     <given-names>HT</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Cho</surname>
                     <given-names>MK</given-names>
                  </name>
                    </person-group>. 
                    <article-title>The Henrietta Lacks legacy grows</article-title>. 
                    <source>EMBO Rep</source>. 
                    <year>2013</year>
                    <month>Oct</month>;
                    <volume>14</volume>(
                    <issue>10</issue>):
                    <fpage>849</fpage>. 
                    <pub-id pub-id-type="doi">10.1038/embor.2013.148</pub-id>
                    <pub-id pub-id-type="pmid">24030280</pub-id>
                    <issn>1469-221X</issn>
                </mixed-citation>
         </ref>
         <ref id="b20">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Lasfargues</surname>
                     <given-names>EY</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ozzello</surname>
                     <given-names>L</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Cultivation of human breast carcinomas</article-title>. 
                    <source>J Natl Cancer Inst</source>. 
                    <year>1958</year>
                    <month>Dec</month>;
                    <volume>21</volume>(
                    <issue>6</issue>):
                    <fpage>1131</fpage>–
                    <lpage>47</lpage>.
                    <pub-id pub-id-type="pmid">13611537</pub-id>
                    <issn>0027-8874</issn>
                </mixed-citation>
         </ref>
         <ref id="b21">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Amadori</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bertoni</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Flamigni</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Savini</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>De Giovanni</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Casanova</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Establishment and characterization of a new cell line from primary human breast carcinoma</article-title>. 
                    <source>Breast Cancer Res Treat</source>. 
                    <year>1993</year>
                    <month>Dec</month>;
                    <volume>28</volume>(
                    <issue>3</issue>):
                    <fpage>251</fpage>–
                    <lpage>60</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/BF00666586</pub-id>
                    <pub-id pub-id-type="pmid">8018954</pub-id>
                    <issn>0167-6806</issn>
                </mixed-citation>
         </ref>
         <ref id="b22">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Gazdar</surname>
                     <given-names>AF</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kurvari</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Virmani</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gollahon</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sakaguchi</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Westerfield</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer</article-title>. 
                    <source>Int J Cancer</source>. 
                    <year>1998</year>
                    <month>Dec</month>;
                    <volume>78</volume>(
                    <issue>6</issue>):
                    <fpage>766</fpage>–
                    <lpage>74</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(19981209)78:6&lt;766::AID-IJC15&gt;3.0.CO;2-L</pub-id>
                    <pub-id pub-id-type="pmid">9833771</pub-id>
                    <issn>0020-7136</issn> 
                </mixed-citation>
         </ref>
         <ref id="b23">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Lee</surname>
                     <given-names>AV</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Oesterreich</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Davidson</surname>
                     <given-names>NE</given-names>
                  </name>
                    </person-group>. 
                    <article-title>MCF-7 cells—changing the course of breast cancer research and care for 45 years</article-title>. 
                    <source>J Natl Cancer Inst</source>. 
                    <year>2015</year>
                    <month>Mar</month>;
                    <volume>107</volume>(
                    <issue>7</issue>):
                    <fpage>djv073</fpage>–
                    <lpage>073</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/jnci/djv073</pub-id>
                    <pub-id pub-id-type="pmid">25828948</pub-id>
                    <issn>0027-8874</issn>
                </mixed-citation>
         </ref>
         <ref id="b24">
            <mixed-citation publication-type="webpage">
                    <person-group person-group-type="author">
                        <collab>International Cell Line Authentication Committee</collab>
                    </person-group>. 
                    <source>Naming a Cell Line - ver. 1.6.</source>.
                    <year>2015</year>. 
                    <date-in-citation content-type="access-date" iso-8601-date="2018-04-14">[cited 2018 Apr 18]</date-in-citation> 
                    <comment>Available from:<uri>http://iclac.org/wp-content/uploads/Naming-a-Cell-Line_v1_6.pdf</uri>
               </comment>.
                </mixed-citation>
         </ref>
         <ref id="b25">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Riaz</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>van Jaarsveld</surname>
                     <given-names>MT</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hollestelle</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Prager-van der Smissen</surname>
                     <given-names>WJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Heine</surname>
                     <given-names>AA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Boersma</surname>
                     <given-names>AW</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs</article-title>. 
                    <source>Breast Cancer Res</source>. 
                    <year>2013</year>
                    <month>Apr</month>;
                    <volume>15</volume>(
                    <issue>2</issue>):
                    <fpage>R33</fpage>–
                    <lpage>33</lpage>. 
                    <pub-id pub-id-type="doi">10.1186/bcr3415</pub-id>
                    <pub-id pub-id-type="pmid">23601657</pub-id>
                    <issn>1465-5411</issn>
                </mixed-citation>
         </ref>
         <ref id="b26">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Waks</surname>
                     <given-names>AG</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Winer</surname>
                     <given-names>EP</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Breast Cancer Treatment: A Review</article-title>. 
                    <source>JAMA</source>. 
                    <year>2019</year>
                    <month>Jan</month>;
                    <volume>321</volume>(
                    <issue>3</issue>):
                    <fpage>288</fpage>–
                    <lpage>300</lpage>. 
                    <pub-id pub-id-type="doi">10.1001/jama.2018.19323</pub-id>
                    <pub-id pub-id-type="pmid">30667505</pub-id>
                    <issn>0098-7484</issn>
                </mixed-citation>
         </ref>
         <ref id="b27">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Bertucci</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Borie</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ginestier</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Groulet</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Charafe-Jauffret</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Adélaide</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Identification and validation of an ERBB2 gene expression signature in breast cancers</article-title>. 
                    <source>Oncogene</source>. 
                    <year>2004</year>
                    <month>Apr</month>;
                    <volume>23</volume>(
                    <issue>14</issue>):
                    <fpage>2564</fpage>–
                    <lpage>75</lpage>. 
                    <pub-id pub-id-type="doi">10.1038/sj.onc.1207361</pub-id>
                    <pub-id pub-id-type="pmid">14743203</pub-id>
                    <issn>0950-9232</issn>
                </mixed-citation>
         </ref>
         <ref id="b28">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Sahlberg</surname>
                     <given-names>KK</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hongisto</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Edgren</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mäkelä</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hellström</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Due</surname>
                     <given-names>EU</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells</article-title>. 
                    <article-title>Mol Oncol</article-title>. 
                    <year>2013</year>;
                    <volume>7</volume>(
                    <issue>3</issue>):
                    <fpage>392</fpage>–
                    <lpage>401</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.molonc.2012.10.012</pub-id> 
                    <pub-id pub-id-type="pmid">23253899</pub-id>
                    <issn>1574-7891</issn> 
                </mixed-citation>
         </ref>
         <ref id="b29">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Neve</surname>
                     <given-names>RM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Chin</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Fridlyand</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Yeh</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Baehner</surname>
                     <given-names>FL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Fevr</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes</article-title>. 
                    <source>Cancer Cell</source>. 
                    <year>2006</year>
                    <month>Dec</month>;
                    <volume>10</volume>(
                    <issue>6</issue>):
                    <fpage>515</fpage>–
                    <lpage>27</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.ccr.2006.10.008</pub-id>
                    <pub-id pub-id-type="pmid">17157791</pub-id>
                    <issn>1535-6108</issn>
                </mixed-citation>
         </ref>
         <ref id="b30">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Kao</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Salari</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bocanegra</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Choi</surname>
                     <given-names>YL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Girard</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gandhi</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery</article-title>.
                    <source>PLoS One</source>. 
                    <year>2009</year>.
                    <volume>4</volume>(
                    <issue>7</issue>):
                    <fpage>e6146</fpage>
                    <pub-id pub-id-type="doi">10.1371/journal.pone.0006146</pub-id>
                    <pub-id pub-id-type="pmid">19582160</pub-id>
                    <issn>1932-6203</issn> 
                </mixed-citation>
         </ref>
         <ref id="b31">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Charafe-Jauffret</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ginestier</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Monville</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Finetti</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Adélaide</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Cervera</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Gene expression profiling of breast cell lines identifies potential new basal markers</article-title>. 
                    <source>Oncogene</source>. 
                    <year>2006</year>
                    <month>Apr</month>;
                    <volume>25</volume>(
                    <issue>15</issue>):
                    <fpage>2273</fpage>–
                    <lpage>84</lpage>. 
                    <pub-id pub-id-type="doi">10.1038/sj.onc.1209254</pub-id>
                    <pub-id pub-id-type="pmid">16288205</pub-id>
                    <issn>0950-9232</issn>
                </mixed-citation>
         </ref>
         <ref id="b32">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Lu</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Takai</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Weaver</surname>
                     <given-names>VM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Werb</surname>
                     <given-names>Z</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Extracellular matrix degradation and remodeling in development and disease</article-title>. 
                    <source>Cold Spring Harb Perspect Biol</source>. 
                    <year>2011</year>
                    <month>Dec</month>;
                    <volume>3</volume>(
                    <issue>12</issue>):
                    <fpage>a005058</fpage>. 
                    <pub-id pub-id-type="doi">10.1101/cshperspect.a005058</pub-id>
                    <pub-id pub-id-type="pmid">21917992</pub-id>
                    <issn>1943-0264</issn>
                </mixed-citation>
         </ref>
         <ref id="b33">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Dai</surname>
                     <given-names>X</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Xiang</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Li</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bai</surname>
                     <given-names>Z</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Cancer hallmarks, biomarkers and breast cancer molecular subtypes</article-title>. 
                    <source>J Cancer</source>. 
                    <year>2016</year>
                    <month>Jun</month>;
                    <volume>7</volume>(
                    <issue>10</issue>):
                    <fpage>1281</fpage>–
                    <lpage>94</lpage>. 
                    <pub-id pub-id-type="doi">10.7150/jca.13141</pub-id>
                    <pub-id pub-id-type="pmid">27390604</pub-id>
                    <issn>0378-2360</issn>
                </mixed-citation>
         </ref>
         <ref id="b34">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Wang</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Elledge</surname>
                     <given-names>SJ</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Ubc13/Rnf8 ubiquitin ligases control foci formation of the Rap80/Abraxas/Brca1/Brcc36 complex in response to DNA damage</article-title>. 
                    <source>Proc Natl Acad Sci USA</source>. 
                    <year>2007</year>
                    <month>Dec</month>;
                    <volume>104</volume>(
                    <issue>52</issue>):
                    <fpage>20759</fpage>–
                    <lpage>63</lpage>. 
                    <pub-id pub-id-type="doi">10.1073/pnas.0710061104</pub-id>
                    <pub-id pub-id-type="pmid">18077395</pub-id>
                    <issn>0027-8424</issn>
                </mixed-citation>
         </ref>
         <ref id="b35">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Gradisnik</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Trapecar</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rupnik</surname>
                     <given-names>MS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Velnar</surname>
                     <given-names>T</given-names>
                  </name>
                    </person-group>. 
                    <article-title>HUIEC, Human intestinal epithelial cell line with differentiated properties: process of isolation and characterisation</article-title>. 
                    <source>Wien Klin Wochenschr</source>. 
                    <year>2015</year>
                    <month>Dec</month>;
                    <volume>127</volume>(
                    <issue>S5</issue>
                    <supplement>Suppl 5</supplement>):
                    <fpage>S204</fpage>–
                    <lpage>9</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s00508-015-0771-1</pub-id>
                    <pub-id pub-id-type="pmid">25821058</pub-id>
                    <issn>0043-5325</issn>
                </mixed-citation>
         </ref>
         <ref id="b36">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Naranda</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gradišnik</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gorenjak</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Vogrin</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Maver</surname>
                     <given-names>U</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Isolation and characterization of human articular chondrocytes from surgical waste after total knee arthroplasty (TKA)</article-title>. 
                    <source>PeerJ</source>. 
                    <year>2017</year>
                    <month>Mar</month>;
                    <volume>5</volume>:
                    <fpage>e3079</fpage>. 
                    <pub-id pub-id-type="doi">10.7717/peerj.3079</pub-id>
                    <pub-id pub-id-type="pmid">28344902</pub-id>
                    <issn>2167-8359</issn> 
                </mixed-citation>
         </ref>
         <ref id="b37">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Lacroix</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Haibe-Kains</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hennuy</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Laes</surname>
                     <given-names>JF</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lallemand</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gonze</surname>
                     <given-names>I</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Gene regulation by phorbol 12-myristate 13-acetate in MCF-7 and MDA-MB-231, two breast cancer cell lines exhibiting highly different phenotypes</article-title>. 
                    <source>Oncol Rep</source>. 
                    <year>2004</year>
                    <month>Oct</month>;
                    <volume>12</volume>(
                    <issue>4</issue>):
                    <fpage>701</fpage>–
                    <lpage>7</lpage>. 
                    <pub-id pub-id-type="doi">10.3892/or.12.4.701</pub-id>
                    <pub-id pub-id-type="pmid">15375488</pub-id>
                    <issn>1021-335X</issn>
                </mixed-citation>
         </ref>
         <ref id="b38">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Hiscox</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Baruha</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Smith</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bellerby</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Goddard</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Jordan</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan</article-title>. 
                    <source>BMC Cancer</source>. 
                    <year>2012</year>
                    <month>Oct</month>;
                    <volume>12</volume>(
                    <issue>1</issue>):
                    <fpage>458</fpage>. 
                    <pub-id pub-id-type="doi">10.1186/1471-2407-12-458</pub-id>
                    <pub-id pub-id-type="pmid">23039365</pub-id>
                    <issn>1471-2407</issn>
                </mixed-citation>
         </ref>
         <ref id="b39">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Larramendy</surname>
                     <given-names>ML</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lushnikova</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Björkqvist</surname>
                     <given-names>AM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wistuba</surname>
                     <given-names>II</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Virmani</surname>
                     <given-names>AK</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Shivapurkar</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Comparative genomic hybridization reveals complex genetic changes in primary breast cancer tumors and their cell lines</article-title>. 
                    <source>Cancer Genet Cytogenet</source>. 
                    <year>2000</year>
                    <month>Jun</month>;
                    <volume>119</volume>(
                    <issue>2</issue>):
                    <fpage>132</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/S0165-4608(99)00226-5</pub-id>
                    <pub-id pub-id-type="pmid">10867149</pub-id>
                    <issn>0165-4608</issn>
                </mixed-citation>
         </ref>
         <ref id="b40">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Nestor</surname>
                     <given-names>CE</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ottaviano</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Reinhardt</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Cruickshanks</surname>
                     <given-names>HA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mjoseng</surname>
                     <given-names>HK</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>McPherson</surname>
                     <given-names>RC</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Rapid reprogramming of epigenetic and transcriptional profiles in mammalian culture systems</article-title>. 
                    <source>Genome Biol</source>. 
                    <year>2015</year>
                    <month>Feb</month>;
                    <volume>16</volume>(
                    <issue>1</issue>):
                    <fpage>11</fpage>. 
                    <pub-id pub-id-type="doi">10.1186/s13059-014-0576-y</pub-id>
                    <pub-id pub-id-type="pmid">25648825</pub-id>
                    <issn>1474-7596</issn>
                </mixed-citation>
         </ref>
         <ref id="b41">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Widschwendter</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Jones</surname>
                     <given-names>PA</given-names>
                  </name>
                    </person-group>. 
                    <article-title>DNA methylation and breast carcinogenesis</article-title>. 
                    <source>Oncogene</source>. 
                    <year>2002</year>
                    <month>Aug</month>;
                    <volume>21</volume>(
                    <issue>35</issue>):
                    <fpage>5462</fpage>–
                    <lpage>82</lpage>. 
                    <pub-id pub-id-type="doi">10.1038/sj.onc.1205606</pub-id>
                    <pub-id pub-id-type="pmid">12154408</pub-id>
                    <issn>0950-9232</issn>
                </mixed-citation>
         </ref>
         <ref id="b42">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Kapałczyńska</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kolenda</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Przybyła</surname>
                     <given-names>W</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zajączkowska</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Teresiak</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Filas</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>..
                    <article-title>2D and 3D cell cultures - a comparison of different types of cancer cell cultures</article-title>. 
                    <source>Arch Med Sci</source>. 
                    <year>2018</year>;
                    <volume>14</volume>(
                    <issue>14</issue>):
                    <fpage>910</fpage>-
                    <lpage>9</lpage>. 
                    <pub-id pub-id-type="doi">10.5114/aoms.2016.63743</pub-id>
                    <pub-id pub-id-type="pmid">30002710</pub-id>
                    <issn>1734-1922</issn> 
                </mixed-citation>
         </ref>
         <ref id="b43">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Hsieh</surname>
                     <given-names>C-H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Chen</surname>
                     <given-names>Y-D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Huang</surname>
                     <given-names>S-F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wang</surname>
                     <given-names>H-M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wu</surname>
                     <given-names>M-H</given-names>
                  </name>
                    </person-group>. 
                    <article-title>The effect of primary cancer cell culture models on the results of drug chemosensitivity assays: the application of perfusion microbioreactor system as cell culture vessel</article-title>.
                    <source>Biomed Res Int</source>. 
                    <year>2015</year>;
                    <volume>2015</volume>:
                    <fpage>470283</fpage>. 
                    <pub-id pub-id-type="doi">10.1155/2015/470283</pub-id> 
                    <pub-id pub-id-type="pmid">25654105</pub-id>
                    <issn>2314-6133</issn> 
                </mixed-citation>
         </ref>
         <ref id="b44">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Bulysheva</surname>
                     <given-names>AA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bowlin</surname>
                     <given-names>GL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Petrova</surname>
                     <given-names>SP</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Yeudall</surname>
                     <given-names>WA</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Enhanced chemoresistance of squamous carcinoma cells grown in 3D cryogenic electrospun scaffolds</article-title>. 
                    <source>Biomed Mater</source>. 
                    <year>2013</year>
                    <month>Oct</month>;
                    <volume>8</volume>(
                    <issue>5</issue>):
                    <fpage>055009</fpage>. 
                    <pub-id pub-id-type="doi">10.1088/1748-6041/8/5/055009</pub-id>
                    <pub-id pub-id-type="pmid">24057893</pub-id>
                    <issn>1748-6041</issn>
                </mixed-citation>
         </ref>
         <ref id="b45">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Fackler</surname>
                     <given-names>MJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lopez Bujanda</surname>
                     <given-names>Z</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Umbricht</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Teo</surname>
                     <given-names>WW</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Cho</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zhang</surname>
                     <given-names>Z</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer</article-title>. 
                    <source>Cancer Res</source>. 
                    <year>2014</year>
                    <month>Apr</month>;
                    <volume>74</volume>(
                    <issue>8</issue>):
                    <fpage>2160</fpage>–
                    <lpage>70</lpage>. 
                    <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-3392</pub-id>
                    <pub-id pub-id-type="pmid">24737128</pub-id>
                    <issn>0008-5472</issn>
                </mixed-citation>
         </ref>
         <ref id="b46">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Christgen</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lehmann</surname>
                     <given-names>U</given-names>
                  </name>
                    </person-group>. 
                    <article-title>MDA-MB-435: the questionable use of a melanoma cell line as a model for human breast cancer is ongoing</article-title>. 
                    <source>Cancer Biol Ther</source>. 
                    <year>2007</year>
                    <month>Sep</month>;
                    <volume>6</volume>(
                    <issue>9</issue>):
                    <fpage>1355</fpage>–
                    <lpage>7</lpage>. 
                    <pub-id pub-id-type="doi">10.4161/cbt.6.9.4624</pub-id>
                    <pub-id pub-id-type="pmid">17786032</pub-id>
                    <issn>1538-4047</issn>
                </mixed-citation>
         </ref>
         <ref id="b47">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Dvořánková</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Szabo</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lacina</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kodet</surname>
                     <given-names>O</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Matoušková</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Smetana</surname>
                     <given-names>K</given-names>
                     <suffix>Jr</suffix>
                  </name>
                    </person-group>. 
                    <article-title>Fibroblasts prepared from different types of malignant tumors stimulate expression of luminal marker keratin 8 in the EM-G3 breast cancer cell line</article-title>. 
                    <source>Histochem Cell Biol</source>. 
                    <year>2012</year>
                    <month>May</month>;
                    <volume>137</volume>(
                    <issue>5</issue>):
                    <fpage>679</fpage>–
                    <lpage>85</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s00418-012-0918-3</pub-id>
                    <pub-id pub-id-type="pmid">22270320</pub-id>
                    <issn>0948-6143</issn>
                </mixed-citation>
         </ref>
         <ref id="b48">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Hoarau-Véchot</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rafii</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Touboul</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Pasquier</surname>
                     <given-names>J</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Halfway between 2D and ANIMAL MODELS: Are 3D cultures the ideal tool to study cancer-microenvironment interactions?</article-title>.
                    <source>Int J Mol Sci</source>. 
                    <year>2018</year>
                    <month>Jan</month>;
                    <volume>19</volume>(
                    <issue>1</issue>):
                    <fpage>181</fpage>. 
                    <pub-id pub-id-type="doi">10.3390/ijms19010181</pub-id>
                    <pub-id pub-id-type="pmid">29346265</pub-id>
                    <issn>1661-6596</issn>
                </mixed-citation>
         </ref>
         <ref id="b49">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Sotiriou</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Neo</surname>
                     <given-names>SY</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>McShane</surname>
                     <given-names>LM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Korn</surname>
                     <given-names>EL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Long</surname>
                     <given-names>PM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Jazaeri</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Breast cancer classification and prognosis based on gene expression profiles from a population-based study</article-title>. 
                    <source>Proc Natl Acad Sci USA</source>. 
                    <year>2003</year>
                    <month>Sep</month>;
                    <volume>100</volume>(
                    <issue>18</issue>):
                    <fpage>10393</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1073/pnas.1732912100</pub-id>
                    <pub-id pub-id-type="pmid">12917485</pub-id>
                    <issn>0027-8424</issn>
                </mixed-citation>
         </ref>
         <ref id="b50">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Fan</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Oh</surname>
                     <given-names>DS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wessels</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Weigelt</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Nuyten</surname>
                     <given-names>DS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Nobel</surname>
                     <given-names>AB</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Concordance among gene-expression-based predictors for breast cancer</article-title>. 
                    <source>N Engl J Med</source>. 
                    <year>2006</year>
                    <month>Aug</month>;
                    <volume>355</volume>(
                    <issue>6</issue>):
                    <fpage>560</fpage>–
                    <lpage>9</lpage>. 
                    <pub-id pub-id-type="doi">10.1056/NEJMoa052933</pub-id>
                    <pub-id pub-id-type="pmid">16899776</pub-id>
                    <issn>0028-4793</issn>
                </mixed-citation>
         </ref>
         <ref id="b51">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Lehmann</surname>
                     <given-names>BD</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bauer</surname>
                     <given-names>JA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Chen</surname>
                     <given-names>X</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sanders</surname>
                     <given-names>ME</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Chakravarthy</surname>
                     <given-names>AB</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Shyr</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies</article-title>. 
                    <source>J Clin Invest</source>. 
                    <year>2011</year>
                    <month>Jul</month>;
                    <volume>121</volume>(
                    <issue>7</issue>):
                    <fpage>2750</fpage>–
                    <lpage>67</lpage>. 
                    <pub-id pub-id-type="doi">10.1172/JCI45014</pub-id>
                    <pub-id pub-id-type="pmid">21633166</pub-id>
                    <issn>0021-9738</issn>
                </mixed-citation>
         </ref>
         <ref id="b52">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Hynds</surname>
                     <given-names>RE</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Vladimirou</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Janes</surname>
                     <given-names>SM</given-names>
                  </name>
                    </person-group>. 
                    <article-title>The secret lives of cancer cell lines</article-title>. 
                    <source>Dis Model Mech</source>. 
                    <year>2018</year>
                    <month>Nov</month>;
                    <volume>11</volume>(
                    <issue>11</issue>):
                    <fpage>dmm037366</fpage>. 
                    <pub-id pub-id-type="doi">10.1242/dmm.037366</pub-id>
                    <pub-id pub-id-type="pmid">30459183</pub-id>
                    <issn>1754-8403</issn>
                </mixed-citation>
         </ref>
         <ref id="b53">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Korch</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Spillman</surname>
                     <given-names>MA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Jackson</surname>
                     <given-names>TA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Jacobsen</surname>
                     <given-names>BM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Murphy</surname>
                     <given-names>SK</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lessey</surname>
                     <given-names>BA</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination</article-title>.
                    <source>Gynecol Oncol</source>. 
                    <year>2012</year>;
                    <volume>127</volume>(
                    <issue>1</issue>):
                    <fpage>241</fpage>-
                    <lpage>8</lpage> 
                    <pub-id pub-id-type="doi">10.1016/j.ygyno.2012.06.017</pub-id>.
                    <pub-id pub-id-type="pmid">22710073</pub-id>
                    <issn>0090-8258</issn>
                </mixed-citation>
         </ref>
         <ref id="b54">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Gillet</surname>
                     <given-names>J-P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Varma</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gottesman</surname>
                     <given-names>MM</given-names>
                  </name>
                    </person-group>. 
                    <article-title>The clinical relevance of cancer cell lines</article-title>. 
                    <source>J Natl Cancer Inst</source>. 
                    <year>2013</year>;
                    <volume>105</volume>(
                    <issue>7</issue>):
                    <fpage>452</fpage>-
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/jnci/djt007</pub-id>.
                    <pub-id pub-id-type="pmid">23434901</pub-id>
                    <issn>0027-8874</issn> 
                </mixed-citation>
         </ref>
         <ref id="b55">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Wilding</surname>
                     <given-names>JL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bodmer</surname>
                     <given-names>WF</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Cancer cell lines for drug discovery and development</article-title>. 
                    <source>Cancer Res</source>. 
                    <year>2014</year>
                    <month>May</month>;
                    <volume>74</volume>(
                    <issue>9</issue>):
                    <fpage>2377</fpage>–
                    <lpage>84</lpage>. 
                    <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-2971</pub-id> 
                    <pub-id pub-id-type="pmid">24717177</pub-id>
                    <issn>0008-5472</issn> 
                </mixed-citation>
         </ref>
         <ref id="b56">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Fusenig</surname>
                     <given-names>NE</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Capes-Davis</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bianchini</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sundell</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lichter</surname>
                     <given-names>P</given-names>
                  </name>
                    </person-group>. 
                    <article-title>The need for a worldwide consensus for cell line authentication: experience implementing a mandatory requirement at the International Journal of Cancer</article-title>. 
                    <source>PLoS Biol</source>. 
                    <year>2017</year>
                    <month>Apr</month>;
                    <volume>15</volume>(
                    <issue>4</issue>):
                    <fpage>e2001438</fpage>. 
                    <pub-id pub-id-type="doi">10.1371/journal.pbio.2001438</pub-id>
                    <pub-id pub-id-type="pmid">28414712</pub-id>
                    <issn>1544-9173</issn>
                </mixed-citation>
         </ref>
      </ref-list>
   </back>
</article>
